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Cryptosporidium is a small protozoan parasite which causes gastroenteritis in both animals and humans  
(OLSON et al. 2004). Among the Cryptosporidium genus, Cryptosporidium hominis and 
Cryptosporidium parvum are the two most important species infecting humans (XIAO and RYAN 2004, 
RYAN et al. 2016). While C. hominis seems to infect exclusively humans, C. parvum is zoonotic 
(FELTUS et al. 2006). C. parvum is a most important pathogen related to watery diarrhea in ruminant 
livestock, especially in neonate calves. It causes significant economic loss in animal husbandry 
(THOMSON et al. 2017). In humans, cryptosporidiosis can become life-threating in 
immunocompromised individuals such as AIDS patients, or malnourished children (VENTURA et al. 
1997 , HUNTER and NICHOLS 2002). A recent global study covering all enteric diseases has classified 
cryptosporidiosis as the second most relevant pathogen, behind rotavirus, responsible for diarrhea in 
children (KOTLOFF et al. 2012). Importantly, Cryptosporidium has also been associated with outbreaks 
of water-borne diseases worldwide in industrialized countries such as South Korea (MOON et al. 2013), 
Australia (WALDRON et al. 2011), and the Unites States of America (GHARPURE et al. 2019). 
Therefore, Cryptosporidium has not only a tremendous impact on veterinary public health but has also 
to be considered in the context of the “One Health” concept.  
Until now, there is no vaccine available for cryptosporidiosis. Nitazoxanide (NTZ) is the only drug 
approved to date by the US Food and Drug Administration (FDA) for treatment of cryptosporidiosis in 
humans but shows only a limited efficacy (SCHNYDER et al. 2009), especially in the most vulnerable 
target groups  (CABADA and WHITE. 2010, MEAD and ARROWOOD 2014). For most anti-
cryptosporidial drugs, the transition from in vitro experimental data to in vivo application represents an 
insuperable challenge, e.g. due to poor system bioavailability and to toxicity of drug candidates (LOVE 
et al. 2017, BHALCHANDRA et al. 2018).  
Therefore, the goal of the current study is to evaluate the delivery of therapeutic compounds such as 
NTZ across the multiple membrane layers that protect the intracellular pathogen in order to improve 
bioavailability, thus increasing the efficacy and reducing dosage of potentially toxic anti-cryptosporidial 
compounds. Cell-penetrating peptides (CPPs) are promising candidates in drug delivery (KRISTENSEN 
et al. 2016). CPPs in general are short polycationic peptides (7-30 residues) which have been applied in 
various studies to improve delivery of small molecules including DNA, RNA, and certain pharmaceutics 
into cells (BECHARA and SAGAN 2013, DINCA et al. 2016). CPPs cross the blood-brain barrier and 
have been demonstrated to penetrate through biological membranes into cytoplasmic and nuclear 
compartments (STALMANS et al. 2015). Interestingly, CPPs do not lose their properties when they are 
attached to cargos of different structure and size. The potential of octaarginine to greatly enhance 
efficacy of drugs has been shown for other intracellular parasites such as Plasmodium (SPARR et al. 




as delivery vehicle for small molecules into Cryptosporidium. Two specific objectives were established. 
Firstly, the application of octaarginine to deliver plasmid DNA for transfection purpose was developed 
(PUBLICATION 1). Secondly, the coupling of octaariginine to NTZ to improve its efficacy was 

























2. Literature review 
2.1 Biology and taxonomic status 
Cryptosporidium was first described and classified as a protozoon of uncertain taxonomic status by 
Ernest Edward Tyzzer based on its asexual and sexual stages (TYZZER 1907). Later, ultrastructural 
studies on Cryptosporidium found that this genus possesses a special attachment organelle, which is 
considered a key feature typical for the genus Cryptosporidium. Morphology, particularly of oocysts, 
development biology, and host specificity are other classical features to allocate cryptosporidia to a 
certain species, complying with the international code of Zoological Nomenclature (ICZN) rules. With 
the achievements of molecular biology, gene sequence information has been widely applied in  defining 
new species of Cryptosporidium  Although Cryptosporidium is still allocated to the phylum 
Apicomplexa, this genus distinctly differs from other members of this phylum e.g. by lacking an 
apicoplast and any trace of the apicoplast genome, and mitochondrion (ZHU et al. 2000). Moreover, 
motility and the invasion process differ from other apicomplexa (WETZEL et al. 2005). Meanwhile, 
based on microscopy, biochemical and genomic data, Cryptosporidium is officially classified into the 









Genus: Cryptosporidium Tyzzer, 1970 
2. 1.1 Life cycle of Cryptosporidium 
Cryptosporidium infection is initiated by ingestion of sporulated oocysts from the environment, e.g. 
food or water contaminated with feces that are excreted by an infected host (LEITCH and HE 2011). 
Unlike oocysts of typical coccidia, Cryptosporidium oocysts are already sporulated and thus fully 
infective upon excretion. Under the activity of digestive enzymes such as those produced by the pancreas 
and bile salts, the excystation process occurs in the small intestine of the host. Four banana shaped 
sporozoites of 3-5 µm length are liberated from each oocyst and invade the brush border of enterocytes 
but do not penetrate to the host cell membrane as other apicomplexa do. In contrast, Cryptosporidium 




(PV) around the parasites. The PV thus remains extracytoplasmatic although the parasite is located 
intracellular since it is fully surrounded by host cell membrane.  
A particular feature of the PV is an actin disc that is formed at the basal area underneath the attached 
parasite and probably serves to transport nutrients from the cytoplasm to the PV (“feeder organelle”) 
during the internalization process, the sporozoites become spherical and are now called trophozoites (1-
2 µm) (BOROWSKI et al. 2010). The trophozoites start to replicate by transforming into meronts. 
During the asexual replication in type I meronts 6-8 merozoites develop in each meront. Merozoites 
have a similar structure as sporozoites with a small size (0.4 ×1.0 µm). Type 1 merozoites infect adjacent 
epithelial cells, developing again into trophozoites and then type II meronts. Merozoites produced by 
type II meronts initiate the sexual replication. During this phase, macrogamonts (4 x 6 µm) and 
microgamonts (2 x 2 µm) are formed (LEITCH and HE 2011). Microgametes are released from 
microgamonts and fertilize macrogamonts to form diploid zygotes that transform into oocysts. During 
sporulation of the oocysts meiosis occurs resulting in 4 haploid sporozoites per oocyst. A firm oocyst 
wall is formed.  Approximately 80% of oocysts produced in the small intestine are considered thick 
walled and the others are thin-walled (FAYER 2008). Thin-walled oocysts are described to be 
responsible for autoinfection whereas the thick-walled oocysts are released with the feces to infect new 
hosts and have the capacity to survive for a long time in the environment. Through the life cycle of 
Cryptosporidium, autoinfection occurs at two stages: first by recycling of merozoites of type I meronts 







Figure 1: Diagrammatic representation of the life cycle of Cryptosporidium ( Image adopted 
from LENDNER AND DAUGSCHIES 2014)  
2.1.2 The formation of the parasitophorous vacuole (PV) 
The invasion process starts when sporozoites attach to the luminal surface of an epithelial enterocyte. 
At that moment, contents of rhoptries, micronemes and dense granules are excreted at the anterior tip of 
the sporozoite (FAYER 2008). Apical proteins have been demonstrated to be essential in the invasion 
process (CHEN et al. 2004).  The engulfing of parasite and the establishment of the PV are related to 
swelling of the host cell microvilli as aquaporin I and the sodium-glucose cotransporter (SGLTI) are 
recruited to the host cell-parasite interface (CHEN et al. 2005). As a result, the PV is formed as a bubble-
like structure induced by both parasite and host cell. Moreover, an electron dense band subsequently 
matures into a unique structure, the so-called feeder organelle that gives the parasite access to nutrient 
of the host cell for its own development (CHEN et al. 2005, ZHU 2008). It is assumed that the lack of 
efficient anti-cryptosporidial drugs reflects the fact that intracellular stages are protected by the PV and 
not easily accessible to drug treatment (MIYAMOTO and ECKMANN 2015) 
2.1.3 Metabolic pathways of C. parvum  
Cryptosporidium parvum has a genome size of 9.1 Mb (ABRAHAMSEN et al. 2004) which is thus 




Toxoplasma gondii (80 Mb) (GARDNER et al. 2002). C. parvum lacks mitochondria, the apicoplast, 
and genes coding for Krebs cycle, but it still possesses genes which encode for mitochondrial proteins, 
particularly TOM40 and TIM17, and chaperons like HSP70 and HSP80. However, C. parvum has lost 
most de novo synthesis capacities to produce fatty acids, amino acids and nucleosides, and thus this 
parasite almost completely depends on the nutrient sources provided by the host cell (ZHU  2008).  
2.2 Epidemiology 
2.2.1 Cryptosporidiosis in humans 
Cryptosporidium infection is characterized by self –limiting diarrhea, nausea, vomiting and abdominal 
pain. Immunocompetent people can recover by themselves after 2-3 weeks (LEITCH and HE 2011, RAJ 
MAINALI et al. 2013). However, the infection can cause mortality, malabsorption and wasting in 
immunocompromised people such as HIV patients or malnourished children. In developing countries, 
cryptosporidiosis is the second most frequent diarrhea pathogen associated with mortality in children, 
just after Rotavirus  (KOTLOFF et al. 2013). Annually, there are more than 200000 children worldwide 
who die because of Cryptosporidium infection (NASRIN et al. 2013). Most of these cases are associated 
to malnutrition and poor hygiene and unfavorable living conditions in developing countries in Asia and 
Africa (MONDAL et al. 2009). Cryptosporidium infection in early childhood has a permanent influence 
on child growth, which is associated with growth retardation, malnutrition, cognitive deficits and 
impaired immune response (MØLBAK et al. 1997, RYAN et al. 2016). In Germany, human 
cryptosporidiosis cases have been reported annually to range from 900 to 1400 cases between 2008 and 
2012 (GERTLER et al. 2015). 
2.2.2 Cryptosporidiosis in animals 
Cryptosporidium is a common parasite which infects both domestic and wild animals worldwide. 
Ruminants are common hosts for Cryptosporidium infection, particularly neonate animals. It has been 
shown in epidemiological reports, that the prevalence and severity of cryptosporidiosis is related to the 
age of animals, and young animals generally present higher prevalence than adults (SANTÍN et al. 2004, 
MADDOX-HYTTEL et al. 2006, FAYER et al. 2007). Cryptosporidiosis in neonate cattle may lead to 
profuse watery diarrhea, dehydration, weight loss, and reduced appetite, and in some cases death can 
occur (THOMSON et al. 2017). C. parvum occurs worldwide and its prevalence in pre-weaned calves   
is estimated to range from 3.4 to 96.6 % (THOMSON et al. 2017), in Europe prevalence from 20-40% 
has been reported based on  evaluation of routine diagnostic records  (JOACHIM et al. 2003). Recent 
epidemiological studies revealed much higher prevalence in Germany and it was supposed that almost 




Cryptosporidium species, C. parvum, C. bovis, C. andersoni and C. ryanae, have been reported (XIAO 
and PENG 2008). Among them, only C. parvum is considered to be pathogenic and zoonotic.  
2.2.3 Transmission pathway and water-borne disease 
Cryptosporidium oocysts are transmitted among hosts via the fecal-oral route, which includes a direct 
and an indirect pathway. The direct transmission occurs during the contact with feces of infected 
animals, while the indirect transmission occurs by ingestion of contaminated water or food.  
Cryptosporidium is responsible for large waterborne outbreaks in developed countries (KARANIS et al. 
2007). In a recent study, it was stated that Cryptosporidium is responsible for more than 8 million cases 
of foodborne illness every year (RYAN et al. 2018). Rainfall and water flooding contribute to the spread 
of pathogens in general, including Cryptosporidium. For instance, an outbreak occurred in Halle, 
Germany, where 24 cases of cryptosporidiosis were documented 6 weeks after the river Saale 
overflowed the floodplains and parts of the city (GERTLER et al. 2015). Most attention was attracted 
to waterborne cryptosporidiosis following a large outbreak in Milwaukee that was reported to have 
affected over 400000 people (KENZIE et al. 1994). This outbreak was obviously not zoonotic since C. 
hominis was identified as the causative agent (SULAIMAN et al. 2001).  
2.2.4 Detection and diagnosis  
There are various methods to detect Cryptosporidium in fecal samples such as microscopy (with or 
without staining of samples), immunofluorescent labeling and genetic evaluation.  
Microscopy  
Modified Ziehl-Neelsen (MZN) staining has been proposed as the golden standard in Cryptosporidium 
diagnosis. Cryptosporidium oocysts are stained by MZN red on a blue background. However, it requires 
technical expertise in interpretation when just few oocysts are present since the samples may contain 
Cryptosporidium oocyst-like bodies such as fungal spores or, in human feces, oocysts of Cyclospora. 
The negative staining with strong carbol fuchsin (HEINE staining) is frequently used to screen samples 
for Cryptosporidium oocysts because it is fast and inexpensive. However, the sensitivity is lower than 
reported for MZN (POTTERS and VAN ESBROECK 2010).  
Immunofluorescence assay 
Direct or indirect immunofluorescence assays (DFA or IFA) provide higher sensitivity than microscopy. 
However, these methods may be not affordable depending on the economic situation. Moreover, they 
require advanced technological equipment as a UV microscope for visualizing (CHALMERS and 





Commercial kits are often based on enzymimmuno assay (EIA) methodology to detect Cryptosporidium 
antigen in stool samples. Attractive features of these kits are that they are simple to use, time saving and 
do not demand any special equipment like laboratory microscopes. However, they are normally quite 




Molecular techniques have been widely applied to detect Cryptosporidium in a variety of types of 
samples such as feces, tissue, water or foods. Different house-keeping genes can be targeted to detect 
Cryptosporidium such as 18S rRNA, heat shock protein (Hsp70), Cryptosporidium oocyst wall protein 
(COWP) (XIAO and RYAN 2004). The benefits of the molecular technique are not only high sensitivity 
and specificity for Cryptosporidium but also that they have the capacity to differentiate the various 
species of this parasite, allowing to distinguish Cryptosporidium species in clinical samples or in the 
environment  (CHALMERS and KATZER 2013). The 60-kDA glycoprotein gene (GP60) is the most 
popular marker and is used for subgenotyping of C. parvum or C. hominis (WIELINGE et al. 2008, 
ZAHEHI et al. 2016). GP60 subgenotyping enables epidemiologic evaluation and comparison of the 
distribution of subtypes of Cryptosporidum spp. among different studies, countries and hosts.  Real time- 
PCR is also a commonly applied and useful molecular method. Depending on the selection of  the most 
suitable primers and probes, RT-PCR is much more sensitive than conventional methods and can detect 
as few as 2 oocysts in a sample  (HADFIELD et al. 2011). In addition, RT-PCR may be used to quantify 
the amount of parasite DNA in samples while conventional PCR does not allow quantification.  
2.3 Therapeutics  
2.3.1 Halofuginone lactate 
Halofuginone lactate is approved for cryptosporidiosis treatment and prophylaxis in neonate calves in 
Europe. This substance is mainly active on the extracellular stages of Cryptosporidium parvum, i.e. 
sporozoites and merozoites. It prevents the intracellular invasion by C. parvum and the forming of 
oocysts (JARVIE et al. 2005). Therefore, it significantly decreases oocyst excretion via feces and 
clinical symptoms related to enteritis (JOACHIM et al. 2003, BOROWSKI et al. 2010,  KEIDEL and 
DAUGSCHIES 2013).  By strategic application of this drug, environmental contamination by oocysts 
and thus infection pressure on other calves may be distinctly reduced. However, the precise mechanism 




Halofuginone is used in suckling calves by oral administration once per day on 7 consecutive days 
(LEFAY et al. 2001, JARVIE et al. 2005). The drug should be used with great care according to 
manufacturer recommendations to avoid toxic effects (JARVIE et al. 2005) 
2.3.2 Paromomycin (PRM) 
PRM belongs to the aminoglycoside antibiotic group and is produced by Streptomyces rimosus. It has 
been applied for Cryptosporidium treatment both in vitro and in vivo (mouse model and in human) 
(STOCKDALE 2008). However, the mechanism how PRM inhibits Cryptosporidium infection is 
unknown. It has been supposed that during the initial asexual development of Cryptosporidium the level 
of protein synthesis is high and that PRM causes translation of mRNA thus inhibiting parasite protein 
synthesis (SHARMA et al. 2014)  In vitro, PMR applied at a dose of 6 mg/ml reduced viability of 
Cryptosporidium oocysts and inhibited growth and invasion (SHARMA et al. 2014). PRM was 
documented to inhibit intracellular stages of Cryptosporidium in cell culture (GRIFFITHS et al. 1998), 
in tissue cultures and in vivo in immunocompromised mice (VINAYAK et al. 2015). PRM has been 
recommended for cryptosporidiosis prophylaxis in calves at a dose of 100 mg/kg for 7 days by oral 
administration.  This treatment reduced oocyst shedding and the number of diarrhea days (AYDOGDU 
et al. 2018). PRM showed only low efficacy in cryptosporidiosis in patients with AIDS. It was found 
that there was no difference in improvement between the PRM treated patient group and placebo patient 
group (WHITE et al. 1994, HEWITT et al. 2000). 
2.3.3 Nitazoxanide (NTZ) 
NTZ is a thiazolide antiparasitic agent that affects a broad spectrum of protozoa and helminthes. Studies 
demonstrated the efficiency of NTZ in Cryptosporidium and Giardia treatment in vitro and in vivo (FOX 
and SARAVOLATZ 2005, RAJ MAINALI et al. 2013). Although the mechanism of NTZ in inhibiting 
Cryptosporidium is not completely understood, it has been attributed to a capacity of NTZ to inhibit 
pyruvate-ferredoxin oxidoreductase (PFOR), an enzyme essential to anaerobic energy metabolism. NTZ 
was demonstrated to inhibit the growth of sporozoites of C. parvum. Moreover, in combination with 
antibiotics such as azithromycine or rifampin NTZ displayed better efficacy of treatment as compared 
to application of NTZ alone (GIACOMETTI et al. 2000). In MDBK cells NTZ at the concentration of 
10 µg/ml reduced parasite growth by more than 90% (THEODOS et al. 1998). Later, the efficacy of 
NTZ in C. parvum isolates (IOWA and KSU1) was evaluated by using real time PCR, and the results 
showed that the growth of parasites was almost completely inhibited by NTZ at a concentration of 12.5 
µg/ml (CAI et al. 2005), confirming the previous studies. In another study, NTZ (25µg/ml) reduced 
oocyst viability, invasion and growth of C. parvum in MDCK cells by 95.1%, 98.1% and 99.1%, 




Up to now, NTZ is the only drug approved by FDA for Cryptosporidium treatment in humans. In one 
study, adults and children infected with Cryptosporidium were treated with NTZ at a dose of 100 mg, 
200 mg and 500 mg, corresponding to age groups 1-3 years, 4-11 years, and over 12 years old, 
respectively. After treatment, the oocyst shedding in stool and diarrhea were reduced significantly as 
compared to a placebo group (ROSSIGNOL et al. 2001). Application of NTZ on 3 consecutive days 
(100 mg twice per day) was recorded to resolve symptoms of disease and to prevent oocyst excretion in 
52 % of malnourished children in Zambia that were serologically HIV negative but nonetheless suffered 
from chronic cryptosporidiosis (AMADI et al. 2002). However, controversial data exist on the efficacy 
of NTZ in the control of cryptospordiosis in children and HIV patients. Placebo controlled trials proved 
that NTZ showed limited efficacy in HIV patients (CABADA and WHITE 2010, MEAD and 
ARROWOOD 2014). Although NTZ displayed little capacity to inhibit Cryptosporidium in 
immunocompromised patients, particularly HIV patients, it is the only licensed drug for 
cryptosporidiosis treatment in humans. Attempts to develop novel pharmaceutics against 
Cryptosporidium have been evaluated in vitro and in vivo, such as oleylphosphocholine (SONZOGNI-
DESAUTELS et al. 2015), pyrazolopyridines inhibiting Cp PI(4) (MANJUNATHA et al. 2017), and 
benzoxaborole (LUNDE et al. 2019). In initial studies, those drugs showed better efficacy than NTZ. 
However, further clinical research in humans is necessary to get these compounds registered for 
treatment.  
2.4 Cell culture models  
A variety of cell lines has been established for cultivating Cryptosporidium. Such models have been 
extensively used for basic research, drug screening, propagation as well as analysis of host-parasite 
interaction. Mostly, the human ileocecal adenocarcinoma cell line (HCT-8) is preferred for in vitro 
studies, however, other cell types such as Madin-Darby bovine kidney cells (MDBK),  Madin-Darby 
canine kidney cells (MDCK), heterogenous human epithelial colorectal adenocarcinoma cells (Caco-2), 
cells derived from human endometrical carcinoma (RL 95-2), or African green monkey kidney cells 
(BS-C-1) (BONES et al. 2019) have been also used in Cryptosporidium research. Although cell lines 
are powerful tools for in vitro studies about Cryptosporidium, it is obvious that they do not allow 
completion of the whole parasite life cycle and are not suited for continuous Cryptosporidium 
propagation. Although it has been reported that oocysts of C. parvum can be recovered in low numbers 
from infected HCT-8 cells, such observations could not be confirmed (GIROUARD et al. 2006). 
In a recently published study, COLO-680N (oesophageal squamous-cell carcinoma) cells were reported 
to be suited for propagation of C. parvum oocysts (MILLER et al. 2018). However, these results could 
not be reproduced by others (ZHENG et al. unpublished). Attempts to produce Cryptosporidium oocysts 




et al. 2013) were published. Although the different stages of Cryptosporidium (asexual and sexual 
stages) have been confirmed by conventional microscopy and ultrastructure analysis by TEM in such 
free-cell cultures, the major limitation is failure to achieve long-term propagation and low yields of 
oocysts (KARANIS 2018). Altogether, all efforts to produce C. parvum oocysts in vitro in suitably high 
numbers have failed so far, and therefore animal models cannot be completely replaced by cell culture 
in Cryptosporidium research by now.  
2.5 In vivo models  
Animal models such as rodents, gnotobiotic piglets (THEODOS et al. 1998,  LEE et al. 2019), and 
calves (KEIDEL and DAUGSCHIES 2013, MANJUNATHA et al. 2017) have been used for 
Cryptosporidium research. They are indispensable for pharmacological investigations, particularly 
screening of drugs and evaluation of efficiency based on clinical parameters. Particularly 
immunodeficient breeds (e.g. SCID mice) (TZIPORI et al. 1995), neonate mice (DOWNEY et al. 2008) 
and INF-γ knockout mice (SONZOGNI-DESAUTELS et al. 2015) proved to be suitable models for in 
vivo research. INF- γ plays an important role in self-limiting Cryptosporidium infection in humans 
(MEAD 2014) by directly inducing enterocyte resistance against Cryptosporidium infection (POLLOK 
et al. 2001). It has been supposed that knocking out of the gene encoding for IFN- γ in mice can at least 
partly mimic the lack of immune response in immunocompromised human patients who particularly 
suffer from Cryptosporidium infection (MANJUNATHA et al. 2017). A major advantage of INF-γ 
knockout mice is that they rapidly display clinical symptoms, such as wasting. The  lesions observed in 
the entire small intestine of infected mice resemble those caused by Cryptosporidium infection in 
immunocompromised humans (GRIFFITHS et al. 1998). Hence, the INF-γ knockout mouse model is 
the preferred rodent model and used by many research groups. 
2.6 Vaccination 
Efforts have been undertaken to identify and characterize vaccine candidates both in vitro and in vivo 
(MEAD, 2014). For instance, inoculation with gamma-irradiated C. parvum oocysts prevented clinical 
symptoms and reduced oocyst shedding in dairy calves (JENKINS et al. 2004). Surface antigens of 
Cryptosporidium sporozoites such as glycoprotein Cp15 and P23 are possibly suitable candidates to 
develop a protective vaccine (FEREIG et al. 2018). These antigens provided promising results in goats, 
BALB/c mice, C57BL/6 mice, and Interleukin-12 knockout mice by reducing the number of oocysts 
excreted and clinical symptoms (HE et al. 2005). However, although the process in research on vaccines 




2.7 Control strategies 
2.7.1 In human 
Cryptosporidium is transmitted by zoonotic and non-zoonotic pathways (waterborne, foodborne and 
nosocomial transmission) (VANATHY et al. 2017). Cryptosporidium oocysts are resistant to harsh 
environmental conditions and may survive e.g. at low temperature of -10 oC for 1 week or 4 days in dry 
feces. They are resistant to most common disinfectants such as chlorine-based products at any 
concentration within the concentration range applicable  for drinking water treatment (FAYER 1995, 
CHALMERS and GILES 2010).  
Noticeably, outbreaks of cryptosporidiosis in humans are frequently related to waterborne transmission. 
Therefore, accessing to clean drinking water is crucial to avoid human cryptosporidiosis. Options to 
control the quality of drinking water have been evaluated such as using UV light or filtration before 
supply of drinking water to households. If no oocyst-free drinking water is accessible, boiling is a proper 
measure to inactivate oocysts. Surface water used for recreation or swimming pools may also serve as a 
source of infection. Disinfection of swimming pools by hyperchlorinate is considered an appropriate 
measure. People with diarrhea are strongly recommended to avoid swimming to protect their own health 
and community (GHARPURE et al. 2019). Altogether, good hygiene practices are a crucial key to 
prevention of transmission of cryptosporidiosis in human populations.   
Remarkably, ingestion of only nine oocysts of C. parvum can induce infection in humans (OKHUYSEN 
et al. 1999) while one infected calf may release approximately 1010 oocysts (MOORE et al. 2003).  
Cryptosporidium infections in human populations may be zoonotic (in particular C. parvum) or non-
zoonotic (C. hominis) and thus cannot successfully be controlled by only applying control measures in 
humans. It is estimated that 15% of Cryptosporidium infection of humans are linked to direct or indirect 
contact to infected animals (GHARPURE et al. 2019). To reduce risk of zoonotic transmission it is 
necessary to reduce as much as possible the excretion of infectious oocysts by infected animals and to 
implement the best possible hygienic measures in animal housings. 
2.7.2 In animals 
Effective strategies include a combination of proper hygiene, prophylactic treatment, and best possible 
management of neonate animals (HARP and GOFF 1998, THOMSON et al. 2017). Environmental 
contamination with oocysts is the main source of Cryptosporidium infection of calves. Keeping good 
hygiene practices should consider intensive cleaning of surfaces, pathogen-free drinking water and 
troughs. In farms where calves suffer from diarrhea caused by Cryptosporidium, it is crucial to apply 




because Cryptosporidium oocysts are susceptible to high temperature and desiccation  (FAYER 2004). 
For decontamination of well-cleaned, dry surfaces commercial disinfectant products may be used. A 
collection of suitable products is listed by the German Veterinary Society (Deutsche 
Veterinärmedizinische Gesellschaft, DVG) (column 8b, protozoan parasites). This list is continuously 
updated and freely accessible under “www.desinfektion-dvg.de”.  Keeping newborn calves in well 
cleaned single crates or igloos will reduce exposure to oocysts. Sufficient colostrum application is 
essential. Observation of young calves for signs of gastroenteritis and coproscopical examination in case 
of a suspected outbreak of cryptosporidiosis should be considered by farmers, as well as protection of 
calves from other enteropathogens that may aggravate the disease (GÖHRING et al. 2014).  If it is 
necessary,  treatment with halofuginone has to be initiated as early as possible (within 24 h after birth 
or first observation of disease) and correctly performed (100 µg/kg BW daily over 7 days) 
(SHAHIDUZZAMAN and DAUGSCHIES 2012).  
 2.8. Cell-penetrating peptides (CPPs) 
CPPs are short cationic peptides that consist of less than 30 amino acid residues. The two first discovered 
CPPs are TAT and penetratin. TAT is the transcription-transactivatin (TAT) protein of the human 
immunodeficiency virus (HIV), while penetratin is derived from the Drosophila antennapedia 
homeodomain. FRANKEL and PABO (1988) demonstrated that TAT could penetrate and translocate 
into the cell nucleus and JOLIOT et al (1991) showed that penetratin could be internalized by neuronal 
cells. CPPs possess the capacity to evoke the process of translocation across the cell membrane, 
mitochondrial and nucleus membranes and cross through the blood-brain barrier (LINDGREN et al. 
2000, MÄE and LANGEL 2006). They are able to enter prokaryotic and eukaryotic cells without 
altering cellular integrity. Remarkably, they have the ability to deliver a variety of compounds (cargoes), 
particularly small molecules, nucleic acids, proteins, counting imaging agents, or drug molecules, 
fluorescent probes, metal-binding ligands, etc. into cells (BORRELLI et al. 2018)  
2.8.1 Classification of cell-penetrating peptides 
CPPs can be classified based on different criteria such as the origin (natural or synthetic products), the 
chemical structure, or the mechanism of how they penetrate into the cell. In table 1, CPPs classification 









Table 1: Classification of CPPs according to HABAULT and POYET (2019) 
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Amphipathic 21 Chimeric 
Polyarginines R(n); 6 < n < 12 Cationic 6-12 Synthetic 
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Table 1 continued 
R6W3 RRWWRRWRR Cationic 9 Protein-derived 
NLS CGYGPKKKRKVGG Cationic 13 Protein-derived 








Anionic 28 Protein-derived 
 
2.8.2 Mechanism of cellular uptake of CPPs 
Until now, the exact mechanism of how specific cell-penetrating peptide internalize into cells is not 
completely understood. Most CPPs utilize two or multiple pathways for translocation into the host cells 
(MADANI et al. 2011) which depends not only on the characteristics of the respective CPPs but also on 
experimental conditions. In general, there are two main mechanisms: direct penetration and endocytosis 






































Direct penetration is one pathway leading to membrane translocation. It is fast and energy-independent. 
Various models have been proposed to explain the related mechanisms, such as the carpet-model, pore-
forming, inverted micelles or the membrane thinning model (MADANI et al. 2011). The first step of 
these mechanisms is mostly based on the interaction of positively charged CPPs with the negatively 
charged components of the cell membrane, e.g. bilayer phospholipids and heparin sulfate (HS) 
(MADANI et al. 2011, KAUFFMAN et al. 2015). This process contributes to permanent or temporary 
destabilization of the cell membrane, which facilitates the folding of peptides on the lipid membrane. 
There are many factors such as the concentration, amino acid sequences which influence the 
internalization process (KALAFATOVIC and GIRALT 2017). Normally, the direct penetration happens 
with high concentration of CPPs or when amphipathic CPPs such as transportant analogues and MPG 
(a fusion between a hydrophobic domain from HIV gp41 and hydrophilic domain from the nuclear 
localization sequence of SV40 T-antigen are applied (DUCHARDT et al. 2007).  
The mechanism of direct translocation of penetratin has been explained mainly on the basis of the model 
of the “inverted micelle” (DEROSSI et al. 1998). Electrostatic interaction between CPPs and negatively 
charged compounds of the cell membrane result in local disorder of the phospholipid bilayer, which 
Figure 2: Schematic presentation of cellular uptake mechanism related to CPPs and their 
cargo ( modified drawing from LAYEK 2015) 




forms inverted hexagonal structures. Peptides are encapsulated in the hydrophilic interior environment 
of the micelle. Inversion of the micelle at the inner layer of the membrane leads to peptide release into 
the cytoplasm (KAWAMOTO et al. 2011).  
Endocytosis by phagocytosis or pinocytosis is an energy-dependent process. Phagocytosis is also known 
as “cell eating” and occurs in scavenger cells such as macrophages, neutrophils, and leukocytes. This 
process leads to engulfment of solid particles such as bacteria or protozoan parasites that are enclosed 
into phagosome vesicles. Phagosomes fuse with lysosomes to form phagolysosomes (CLEAL et al. 
2013). In contrast, pinocytosis involves engulfment of liquids or solutes and is referred as “cell 
drinking”. Pinocytosis is important for cellular homeostasis control and occurs in every cell type. 
Pinocytosis is classified as macropinocytosis, clathrin-mediated endocytosis, caveolin-mediated 
endocytosis or clathrin- and caveolin-independent cytosis (JONES 2007, LAYEK et al. 2015). For 
instance, the mechanism of uptake of arginine rich CPPs such as polyarginine or TAT into the cell has 
been demonstrated to occur by macropinocytosis where cell membrane ruffling plays a crucial role 
(KRISTENSEN et al. 2016). Cellular uptake of unconjugated TAT peptide is related to clathrin-
mediated endocytosis, whereas the uptake of conjugated TAT occurs by caveolae-mediated pinocytosis 
(RICHARD et al. 2005). 
Natural α-peptides are rapidly degraded by proteases (HOOK et al. 2005). This is a major concern 
regarding applying these molecules as CPPs for drug delivery (BRUNO et al. 2013). To overcome 
proteolytic degradation, change of conformation (such as using the D-isomer) or β-peptides are 
suggested to increase stability, the latter being synthetic and consisting of homologated proteinogenic 
amino acids, and are considered to be better suited as CPPs (KAMENA et al. 2011). 
By conventional solid-phase peptide coupling, β3 oligoarignine (β-OA) was synthesized from the 
monomeric building block Fmoc- β3hArg(Boc)2 –OH . β-OA has been used in biological investigations 
with promising results. It has been proven to penetrate into bacterial cells, like Escherichia coli and 
Bacillus megaterium, into mouse fibroblast, HeLa cells and Human Foreskin Keratinocytes (HFK). The 
success of penetration into HeLa cells depends on the chain length of transported peptides. Short chain 
peptides (tetramer and hexamer) were found to stick on the cell surfaces while long chain peptides 
(octamer and decamer) accumulated inside the cytoplasm following penetration into the cells and ended 
up in the nuclei. Penetration of β-OA into HFK cells worked both at 4 oC and 37 oC and in the presence 
or absence of cellular metabolism disruptor (NaN3) (SEEBACH et al. 2004). Moreover, β-OA was tested 
for induction of hemolysis in rat and human erythrocytes and was found to be non-hemolytic even at a 
concentration as high as 100 µM. 
In a previous study, fluorescent-labeled β-OA was used to track infected erythrocytes. It was found that 




pathways. Interestingly, β-OA can only go through membranes of erythrocytes when they are infected 
by Plasmodium (KAMENA et al. 2011) and failed to overcome the intact membrane of healthy human 
erythrocytes. From this intriguing result it appears that β-OA may be an interesting candidate for 
delivery of antimalarial drugs to the site of parasite infestation.  Octaarginine was applied to increase 
the efficacy of fosmidomycin against Plasmodium and Mycobacterium in vitro (SPARR et al. 2013). 
Coupling with octaarginine increased the efficacy of fosmidomycine in malaria treatment dramatically 
(IC50 = 4.4 nM) compared with fosmidomycine alone (IC50 = 181.4 nM). In vivo it was shown that β-
OA can even penetrate tissue layers and may thus serve as a transporter e.g. through the skin as 
demonstrated in vivo in a laboratory mouse model (SEEBACH et al. 2004). 
2.9 Electroporation and electroporation-free transfection 
Electroporation is an efficient method using high voltage electric pulses to introduce foreign genes into 
cells to produce transient transfection. However, the transfection by electroporation requires large 
amounts of DNA plasmid of up to 100 µg (POTTER and HELLER 2003). Besides, high voltage 
application may not be suitable for transfection of protozoan parasites and may be harmful e.g. 
apicomplexan sporozoites. Therefore, the amount of C. parvum sporozoites used for electroporation has 
to be quite high with up to107 (VINAYAK et al. 2015, PAWLOWIC et al. 2017). Other options of 
transfection have been studied to overcome problems associated with electroporation. For example, 
cationic polyethylenimine (PEI) was successfully applied to deliver green fluorescent GFP gene into the 
genome of the protozoan parasite Toxoplasma gondii (SALEHI and PENG 2012). In fact, due to the 
electrostatic interaction between the cationic polymer and the negatively charged DNA plasmid, the 
resulting complex protected the DNA from degradation and facilitated uptake of the complex into the 
host cells (SMEDT et al. 2000). Therefore, PEI can be considered for transfection applications for other 
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Cryptosporidiosis is an intestinal disease which occurs in a variety of hosts including animals 
and humans. Until now, there is no vaccine available for this disease. Nitazoxanide (NTZ) is 
the only FDA approved drug for cryptosporidiosis treatment in man, however its efficacy in 
immunocompromised people such as AIDS patients or malnourished children is limited and it 
is not licensed for animals. A major obstacle faced by drugs against intracellular pathogens is 
the transport of the drug into the infected cell and into the parasitophorous vacuole. In this 
study, we have investigated the potential of the cell-penetrating peptide octaarginine to increase 
the uptake of NTZ by cells and thereby to improve its efficacy. For this purpose, octaarginine 
was synthetically attached to NTZ and the resulting complex NTZ-R8 tested for the inhibition 
of Cryptosporidium growth in comparison to unmodified NTZ. The inhibitory properties of 
NTZ and NTZ-R8 were tested both in vitro using the human ileocecal adenocarcinoma (HCT-
8) cell line as well as in vivo on the IFN-γ-knockout mouse model. Both in vitro and in vivo we 
observed a distinct improvement of drug efficacy when NTZ was attached to octaarginine. 
Particularly, the improved survival of infected mice treated with NTZ-R8 encourages further 
evaluation of application of octaarginine as a vehicle for anticryptosporidial compounds to 
develop alternative treatment solutions against this infection. 
Key words: Cryptosporidium, Nitazoxanide, Octaarginine, IFN-γ knockout mice 
Author summary 
Cryptosporidiosis is an important and widely distributed intestinal disease induced by the 
apicomplexan parasite Cryptosporidium parvum in neonate animals and in humans. It can cause 
severe diarrhoea leading to high mortality in young ruminants, infants and immunodeficient 
patients. Currently, no vaccine is available to prevent cryptosporidiosis. Moreover, for man 




efficacy in immunocompromised persons and is not licensed for using in veterinary medicine. 
Developing novel anti-cryptosporidal compounds or increasing the efficacy of existing drugs 
is an urgent need to achieve satisfactory treatment options for Cryptosporidium infection in 
both man and animal. In this study, we evaluated the property of the cell-penetrating peptide 
(CPP) octaarginine to improve the efficiency of NTZ on Cryptosporidium parvum by coupling 
octaarginine to nitazoxanide (NTZ-R8). NTZ-R8 showed significantly higher efficacy as 
compared to NTZ alone in terms of growth inhibition in vitro and increased survival of IFN-γ- 
knockout mice. 
Introduction  
Cryptosporidium spp. is a small protozoan parasite which causes gastroenteritis in both animals 
and humans worldwide. Due to the wide range of hosts and various transmission pathways, 
Cryptosporidium parvum has not only a tremendous impact on animal health but also needs to 
be considered in the context of the “One Health” concept. Cryptosporidiosis in humans is 
characterized by diarrhea, nausea, vomiting, fever, and abdominal pain; however, the disease 
is self-limiting in persons with an intact immune system [1,2]. In contrast, infection of 
immunocompromised patients or malnourished children with either C. parvum or C. hominis 
may become life-threating without proper treatments [3,4]. The introduction of highly active 
antiretroviral therapy (HAART) against HIV infection has significantly reduced the incidence 
of fatal Cryptosporidium infection in industrialized countries [5,6]. Nevertheless, 
Cryptosporidium infection was listed in 2013 by the Global Enteric Multicenter Study (GEMS) 
as the second leading cause of diarrhoea-associated mortality in children in developing 
countries [4]. While C. parvum is zoonotic and can cause severe disease in both man and 
animals, particularly young ruminants, C. hominis infects exclusively humans. There are no 




disease are rather limited. For chemotherapy of human cryptosporidiosis, nitazoxanide (NTZ) 
is the only FDA-approved drug. However, NTZ shows poor efficacy in immunocompromised 
patients and malnourished children [7, 8] and is not licensed for use in animals. The 
development of new or alternative therapeutic strategies to control cryptosporidiosis is a 
necessity. However, developing fully new drugs is a time consuming and costly process. 
Alternatively, repurposing drugs that are established for other indications or increasing the 
efficacy of available anti-cryptosporidial compounds represent attractive options for widening 
the repertoire of therapeutic solutions. In this study, we opted for the use of the short cell-
penetrating peptide octaarginine to increase uptake to NTZ into Cryptosporidium-infected cells 
and thereby improve its efficacy.  
In recent years, the short polycationic peptide octaarginine has been successfully used as a 
delivery vehicle for drugs as well as plasmid DNA into intracellular parasites [9,10,11]. It has 
been demonstrated that octaarginine dramatically improves efficacy of the experimental anti-
malaria drug fosmidomycin [10]. In the present study, we explored whether coupling of 
octaarginine to the anti-Cryptosporidium drug NTZ facilitates its uptake by infected cells thus 
possibly improving anticryptosporidial efficacy [9 ,10]. For this purpose, octaarginine was 
coupled to NTZ to create the NTZ-R8 conjugate. Importantly, the octaarginine moiety was 
coupled to NTZ via an ester bond and can be released by esterase. The conjugated compound 
was tested both in vitro and in vivo. We found in both cases a distinct improvement of anti-
cryptosporidial activity compared to NTZ alone. These results encourage further investigations 
to clarify the usefulness of this strategy for development of an alternative therapeutic approach 
against cryptosporidiosis.  





Nitazoxanide (NTZ) (Sigma-Aldrich, Darmstadt, Germany) and nitazoxanide-octaarginine 
(NTZ-R8) were dissolved in DMSO (10 mg/ml) and stored in the dark at -20oC. The drugs were 
freshly prepared in infection medium (DMEM supplemented with 2% fetal calf serum, 1% 
antibiotics penicillin/streptomycin, and 1% amphotericin B) for in vitro and in vivo testing.  
Cell culture 
In the in vitro study, human ileocecal adenocarcinoma cells (HCT-8) were seeded into 24-well 
plates at an initial density of 2 x 105 cells/well. The cells were grown up to 70-80% cell 
confluence in 1-2 days in RPMI medium. The growth medium consisted of RPMI medium 
supplemented with 10% fetal calf serum (FCS) (Northumbria, Cramlington, UK), 1% 
antibiotics (penicillin/streptomycin), and 1% amphotericin B. 
Parasites 
Cryptosporidium parvum strain (gp60/ subtype IIa A15G2R1) was isolated from calves 
(Köllitsch, Germany). C. parvum oocysts were passaged every 3 months in calves under 
experimental conditions, and the oocysts were purified from feces following the protocol 
described by Najdrowki et al [12]. Oocysts were stored in PBS, pH= 7.2 (Gibco®, ThermoFisher 
Scientific, Massachusetts, USA) supplemented with penicillin/streptomycin (200 µg/ml) and 
amphotericin B (5 µg/ml) to prevent bacterial and fungal growth at 4oC for up to 3 months until 
use. The storage medium was replaced every 2 weeks. Before usage, the oocysts were bleached 
with cold NaOCl (5.25% diluted 1:1 (v/v) in PBS; pH = 7.2) by incubating on ice for 5 min. 
Oocysts were then washed extensively with cold PBS (3 times) to completely remove NaOCl 
before excystation. In order to obtain free sporozoites, oocysts were resuspended in excystation 
medium (sodium taurocholate -NaT at a final concentration of 0.4% in DMEM medium 




1% of sodium pyruvate) and processed following the protocol as described in Nguyen-Ho-Bao 
et al [11]. 
Uptake of FAM-labeled octaarginine by excysted sporozoites and intracellular 
Cryptosporidium parvum  
6-FAM-labeled octaarginine (10 μg/ml) was added to either free sporozoites or HCT-8 cell 
cultures infected by intracellular stages of C. parvum. Intracellular 6-FAM-labeled octaarginine 
was visualized by direct fluorescence and/ or immunofluorescence assay was applied to detect 
C. parvum using a Leica TCS SP8 laser scanning confocal microscope (Leica, Wetzlar, 
Germany). Sporozoites were centrifuged at 9500 x g for 5 min, followed by a washing step with 
PBS (pH =7.2). All steps of the following protocol were performed at room temperature. 
Sporozoites or infected host cells were fixed with 4% paraformaldehyde (PFA) for 20 min, and 
thereafter washed 3 times with PBS. Then, 4,6-diamidino-2-phenylindole (DAPI; 10µg/ml) was 
added followed by incubation for another 5 min.  In the immunofluorescence assay, the 
permeabilization with 0.2% Triton X-100 for 20 min was performed right after the fixation step. 
Then, 1 % bovine serum albumin (BSA) in PBS was added to block unspecific binding. 
Thereafter, infected cells were incubated for 1 h with a specific primary rat-anti 
Cryptosporidium antibody (Waterborne INC, New Orleans, LA, USA) in PBS containing 1% 
BSA at a dilution of 1: 1000. Goat-anti-rat DylightTM 647 (Rockland, Limerick, USA) was used 
as secondary antibody and the nuclei stained with DAPI. Finally, cells were mounted with 
Fluoromount-G (Southern Biotech, Brimingham, USA) and stored at 4oC until visualization. 
Mitochondrial toxicity test (MTT) 
For MTT 3-(4,5-dimethythiazol2-yl)-2,5-diphenyl tetrazolium bromide was applied to evaluate 
whether NTZ and octaarginine at the chosen concentrations have a negative impact on host cell 




under 5% CO2 until the cell cultures reached 80% confluence. NTZ (25, 20, 15, 10, 5, 1 µg/ml) 
and octaarginine (100, 10 and 1 µg/ml) were freshly diluted in culture medium and added to 
the growing cultures for 24 h. Subsequently, 10 µl MTT solution (containing tetrazolium dye) 
were added to each well and the plates were further incubated for 4 h. Stop solution (10% SDS/ 
0.01 M HCl) was added to dissolve precipitates of formazan crystals. Absorption was measured 
by spectrophotometry (Anthos 2001) at 595 nm. Each concentration was set in triplicates.  
In vitro inhibition assay  
HCT-8 cells were seeded into 24-well plates (2 x 105 cells/well) and incubated until they 
reached a confluence of 80%. Cells were cultured in RPMI-1640 supplemented with 10% fetal 
calf serum, antibiotics (1% penicillin/streptomycin, 1% amphotericin B), and 1% sodium 
pyruvate. They were incubated at 37°C with 5% CO2. Confluent monolayers were inoculated 
with 2 x 105 oocysts in excystation medium (0.4% NaT in DMEM with 2 % fetal calf serum, 
1% amphotericin B and 1% penicillin/streptomycin, 1% sodium pyruvate) and further 
incubated at 37oC and 5% CO2 for 3 h. Non-excysted oocysts and empty oocyst shells were 
gently removed by washing with PBS for 3 times. NTZ and NTZ-R8 were diluted in growing 
medium at different concentrations (1, 5, 10, 50, 100, 1000 ng/ml) and added to cell cultures 
previously exposed to infection and further incubated (37oC, 5% CO2) for 24 h. Uninfected 
untreated cells served as negative controls. Positive controls were infected cultures that were 
not treated with NTZ or NTZ-R8, respectively. All conditions were set as triplicates.  
RNA extraction. Exactly 24 h post infection, cell culture plates were centrifuged at 1000 x g 
for 10 min to ensure that remaining extracellular stages of the parasite firmly settle on the 
bottom of the well. The culture medium was gently aspirated and cells were harvested by 
directly adding lysis buffer of the RNeasy® Mini Kit (Qiagen, Hilden, Germany) to each well. 
Further extraction of RNA from the samples was done strictly following the instructions of the 




Germany). 1 µg RNA was used to produce respective cDNA according to the instruction 
delivered with the Revert-Aid® first strand cDNA synthesis kit (Thermo Fisher Scientific, 
Darmstadt, Germany). The cDNA was stored at -80oC until further use. 
Real-time PCR. Real-time PCR reactions were performed on a Bio-Rad CFX96 Real-Time 
PCR Detection System using the program two-step SYBR green with primers for 
Cryptosporidium 18S RNA targeting Cp18S-1011F (5′-TTG TTC CTT ACT CCT TCA GCA 
C-3′) and Cp18S-1185R (5′- TCC TTC CTA TGT CTG GAC CTG-3′). The data were 
normalized by the transcription levels of host cell Hs18S rRNA [13] , applying the primer pair 
Hs18S- 1F (5′-GGC GCC CCC TCG ATG CTC TTA-3′) and Hs18S- 1R (5′-CCC CCG GCC 
GTC CCT CTT A-3′). The thermo cycler program for RT-qPCR was: 95°C for 3 min, followed 
by 40 amplification cycles at 95°C for 10 s and 58°C for 30 s. The melting curve analysis was 
performed at a temperature range between 65oC and 95oC. The transcription level of Hs18 
rRNA was applied for both normalization and controls. The following formula were used to 
estimate parasite growth inhibition (PGI%) 
∆𝐶𝑇 = 𝐶𝑇[Cp18S]  − 𝐶𝑇[Hs18S]    
∆∆𝐶𝑇 = ∆𝐶𝑇[sample]  − ∆𝐶𝑇[control]   
PGI % = 100 − (2−△△ 𝐶𝑇) × 100 
Titration of infection dose in IFN-γ knockout mice  
IFN-γ knockout female mice aged 6-12 weeks were randomly pooled into 4 groups of 3 mice 
each. Group 1 served as uninfected control group, whereas mice in groups 2, 3, and 4 were 
inoculated with C. parvum oocysts at a dose of 10000, 5000, or 1000 oocysts per mouse, 
respectively. Determination of individual weight, collection of feces, and scoring of general 




In invo assessment of drug efficacy in INF-γ knockout mice 
Animal experiments were approved by the local ethical committee and the local authority 
(Landersdirektion Sachen, Germany) under the number TVV 07/19. IFN-γ-knockout mice were 
randomly pooled into 3 groups (n = 5). All mice were inoculated by oral gavage with 1000 
oocysts. The trial design is shown in Figure 1. The infected mice were treated daily from day 6 
post infection (dpi), either with 5% DMSO in water (sham treatment), 10 mg NTZ/kg BW 
group, or 2 mg NTZ-R8/kg BW group. All mice were weighed and scored daily by two different 







Estimation of oocyst excretion 
Feces were collected and pooled for each cage daily. Feces were stored at -20 oC until DNA 
extraction. To calculate the number of oocysts passed in 1 g of feces (oocysts per gram = OpG), 
DNA was extracted from 100 mg mouse feces using the Fast DNA Stool kit (Qiagen, Germany) 
according to the instructions of the manufacturer. Quantitative (q)PCR was performed 
following the protocol described in Shahiduzzaman et al [14]. PCR primers amplifying the C. 
parvum hsp70 gene (forward primer 5′-AACTTTAGCTCCAGTTGAGAAAGTACTC -3′; 
reverse primer: CP_hsp70_rvs 5′-CATGGCTCTTTACCGTTAAAGAATTCC 3′; TaqMan 
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 Challenge with Cryptosporidium oocyst    Treatment      Daily weighing, scoring and feces 
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probe: HSP_70_SNA 5′-AATACGTGTAGAACCACCAACCAATACAACATC-3′) were 
used along with the following cycler program: denaturation at 95°C for 15 min, followed by 40 
cycles of denaturation at 94°C for 15 s, and annealing at 60°C for 1 min. The total volume of 
each PCR reaction contained 25 µl consisting of 1X Master Mix (Thermo Fisher Scientific, 
Darmstadt, Germany) 0.3 µM of forward primer and 0.9 µM of reverse primer, 0.2 µM of 
Hsp70 probe labelled at the 5′-end with the 6-carboxyfluorescein reporter dye (FAM) and at 
the 3′-end with the 6-carboxytetramethylrhodamine quencher dye (TAMRA). The qPCR 
reactions were performed applying the Bio-Rad CFX96 Touch Real-Time PCR Detection 
System and PCR plates (Bio- Rad Laboratories, Hercules, CA). For qPCR, purified plasmid 
was used to construct the standard curve. OpG were calculated based on the DNA copies as 
followed: (with n= number of DNA copies, a: dilution DNA in µl water, b: milligram of feces 
and 4 = number of sporozoites in one oocyst)  







A sample containing feces obtained from non-infected mice but spiked with known number of 
freshly isolated oocysts was also processed in order to evaluate the correlation of qPCR and the 
actual number of oocysts. 
Histopathology  
Mice were euthanized at day 14 post infection or died during experiment (dead in cage or 
euthanized when they lost more than 20 % of their body weight). For each mouse, a specimen 
from the ileum was collected 2 cm anterior to the cecum. The fragments were flushed and fixed 
in 4% formaldehyde. Fixed samples were processed, embedded in paraffin and were cut into 
slices of 2-3 µm thickness slices were deparaffinized and stained with hematoxylin and eosin. 




microscope with 2x, 4x, 10x, 20x, 40x, and 100x-oil-immersion objectives and 5 megapixel 
digital colour camera (Olympus Deutschland GmbH, Hamburg). The average villus to crypt 
ratio was estimated and the density of C. parvum organisms present in the mucosal epithelium.  
The severity of inflammatory infitrates in the lamina propria and submucosa were graded on a 
scale from 0 = not present, 1 = oligofocal organisms; mild inflammation, 2 = multifocal 
organisms; moderate inflammation, 2 = disseminated organisms; severe inflammation. 
Data analysis 
Data obtained by qPCR were analyzed using Microsoft Excel (Microsoft Corporation, 
Redmond, WA, US). Statistical analyses and graphs were done using GraphPad Prism version 
8.02 (GraphPad Software, Inc., La Jolla, California, US). The survival rate was evaluated by 
Kaplan Meier plot and p-values for survival were calculated by Mantel Cox test. Data used for 
IC50 calculation for NTZ and NTZ-R8, and for estimation of the dose-response-inhibition were 
performed to previous logarithmic transformation. 
Results 
Uptake of FAM-labelled octaarginine by Cryptosporidium  
6-FAM-labeled octaarginine was supplemented to either freshly excysted C. parvum 
sporozoites or C. parvum- infected HCT-8 cell cultures. For extracellular sporozoites, the 
peptide uptake occurred rather rapidly, and within 10 min octaarginine accumulated in the 
parasite nucleus (Figure 2A). The incubation of FAM-labelled octaarginine with C. parvum-
infected HCT-8 monolayers revealed that octaarginine entered the parasitophorous vacuole 
within 1 h of incubation (Figure 2B). These observations confirm the potential of octaarginine 


























Figure 2: (A) Freshly excysted C. parvum sporozoites were incubated with 6-FAM-
Octaarginine (green) for 30 min prior to analysis. (B) Logarithmic culture of C. parvum in 
HCT-8 cells were incubated with FAM-octaarginine for 30 min prior to analysis. Multiple 
stages of the parasites can be seen bearing the green color of the labelled peptide. DAPI was 
used to visualized the nuclei and anti-Cryto antibodies (Red) 
A 







 NTZ-R8 inhibits C. parvum growth in HCT-8 cells 
Nitazoxanide was coupled synthetically to octaarginine in order to generate the conjugate 
molecule, Nitazoxanide-octaarginine (NTZ-R8). An ester bond was used for the coupling of 
two moieties and shall enable the release of the tizoxanide, the active molecule, upon hydrolysis 
by esterase (Figure 3) 
 
 
Before evaluating the activity of NTZ-R8 on the target organism, C. parvum, potential cytotoxic 
effects of NTZ and octaarginine on host cells HCT-8, were evaluated using the MTT test. 
Concentration ranges of 1 to 25 µg NTZ/ml and of 1 to 100 µg octaarginine /ml were tested. 
For both substances no relevant cytotoxicity was found, although cell viability appeared to be 




Figure 3: The chemical structures of tizoxanide, nitazoxanide (NTZ) and nitazoxanide-
octaarginine (NTZ-R8). Red arrow showing the cleavage position by esterase to release 
tizoxanide from NTZ-R8 











In order to test the inhibitory properties of the drugs, HCT-8 cells were infected with C. parvum 
and treated with NTZ or NTZ-R8 at 6 different concentrations (1, 5, 10, 50, 100, 1000 ng/ml). 
These treatment doses have been previously tested by MTT and no toxicity was observed. At 
the highest concentration of 1000 ng/ml, NTZ-R8 and NTZ distinctly inhibited C. parvum 
growth by 97.57% and 79.98%, respectively (Figure 5). IC50 was 60.54 ng/ml (197 nM) for 
NTZ and 4.499 ng/ml (2.9 nM) for NTZ-R8 (Figure 5). Coupling of NTZ to octaarginine (NTZ-








Figure 4: Viability of HCT-8 cells following exposure to NTZ (A) and octaarginine (B) over a 














Titration of infection dose in IFN-γ knockout mice  
Following successful evaluation of the effect of octaarginine on NTZ efficacy in vitro, we 
decided to continue the evaluation in vivo using the established IFN-γ knockout mouse model 
of cryptosporidiosis. Because reports concerning the required number of C. parvum oocysts to 
mount an infection in the mouse are not unanimous, we decided to assess the optimal number 
of oocysts for our experiments. For this purpose, we conducted titration applying different 
numbers of oocysts to infect the mice as followed: G1 (no infection), G2 (10 000 oocysts) G3 
(5000 oocysts) and G4 (1000 oocysts). As shown in figure 6, OpG increased in all infected 
groups (G2, G3, and G4). Although there were no significant differences in oocyst shedding 
between different groups irrespective of the infection dose, mice with the highest inoculation 
dose of 10000 oocyst all mice died on the day 8 while mice of group 3 (5000 oocysts) and group 
4 (1000 oocysts) survived until 11 dpi and 13 dpi, respectively. This indicates that the oocyst 
shedding is not necessarily a read out for disease pathology. For further experiments we decided 
to use the lowest infection dose of 1000 oocysts. All infected mice in the 3 groups revealed the 
Figure 5: Growth inhibition of C. parvum in HCT-8 monolayers by NTZ and NTZ-R8. IC50 NTZ= 
60.54 ng/ml (197 nM) and IC50 NTZ-R8= 4.499 ng/ml (2.9 nM). The data presents ± SEM. The 





clinical symptoms for cryptosporidiosis such as emaciation, dehydration reducing food 








Coupling of NTZ to octaarginine (NTZ-R8) significantly improves the efficacy on 
cryptosporidiosis in the IFN- knockout mouse model. 
In order to assess the effect of NTZ-R8 in the mouse model, several clinical parameters were 
recorded. The weight of mice belonging to the untreated infected control group showed a sharp 
decrease from 6 until 11 day post infection (dpi). Weight loss was also recorded in the two 
treated groups; however, it occurred less rapidly. At 8 dpi, the mice in the control group huddled 
together in a corner of the cage, fur became ruffled, the animals appeared emaciated (weight 
lost nearly 15%) and feces was soft. On 9 dpi two mice died and one mouse was euthanized to 
prevent further suffering since the humane endpoints has been reached. Mice were reluctant to 
move, were hunched and displayed a late response to stimulation. In contrast to the sham treated 
group, mice treated either with NTZ or NTZ-R8 experienced a less dramatic weight loss which 
result in a better survival. Strikingly, weight loss mice treated with NTZ-R8 was stabilized from 
Figure 6: Oocysts shedding of IFN-γ knockout mice measured by qPCR. G1: non-
infected group, G2, G3 and G4: mice were challenged with 10000, 5000 and 1000 




10 dpi and even increased slightly in the last two days of the experiment for most of the animals 
Figure 7. In addition to stabilizing their weight loss, treated animals also showed a significant 
improvement in their active movements and on immediate response under stimulation. Only 









Survival rate  
When comparing the survival rate, we noticed that it dropped dramatically in the sham treated 
group to 40% within 9 dpi and reached 0% by 11 dpi. For the mice group treated with NTZ 
alone (10 mg/kg BW), survival rate dropped to 60% on day 11 and reached 40% by the end of 
experiment at 13 dpi. Strikingly, mice treated with the NTZ-R8 conjugate (2 mg/kg BW) 
showed a better survival with only one mouse dying at 10 dpi and all remaining animals 
surviving until the end of the experiment (Figure 8). Despite the obviously higher survival of 
NTZ-R8 treated animals compared to NTZ only treated animals, the difference was not 
statistically different (P > 0.05). Due to limited availability of the synthetic conjugate NTZ-R8, 
Figure 7: The percentage of weight loss of every IFN-γ knockout mouse during infection 
by C. parvum. Treatment with NTZ or NTZ-R8 was given during the period 6 dpi to 13 




the highest concentration used was 2 mg/kg BW whereas a 5-fold higher dose (10 mg/kg BW) 











All infected mice started shedding oocysts at 2 dpi. Feces samples were pooled per group and 
analyzed by qPCR. On 7 dpi, the mice of shame treated group (5% DMSO/ water) excreted 
3.83 x 108 oocysts/g feces. In the mice treated with NTZ (10 mg/kg BW) or NTZ-R8 (2 mg/kg 
BW), oocyst shedding was reduced as early as the 7 dpi (24 h after initiation of treatment) with 
only 1.19 x 107 and 2.12 x 107 oocysts/g feces, representing a reduction of oocyst excretion of 
96.91 % and 94.49 %; respectively (Figure 9). Oocyst reduction in both treated groups was 
significant at 7 dpi (P < 0.001). These in vivo results are consistent with the inhibition of 
reproduction documented in the in vitro testing in HCT-8 cells.  
Figure 8: Kaplan –Meiser curve for survival estimation of C. parvum infected INF- γ knockout 
mouse. Mice were infected with 1000 oocyst in 0 dpi and gave treatment at 6 dpi. Sham treated 
group served as positive control with DMSO 5%, NTZ: treated group with nitazoxanide at the 
concentration 10 mg/kg BW, and NTZ-R8: treated group with nitazoxanide-octaarginine at the 




During the following 4 days of treatment (6 dpi to 9 dpi), oocyst shedding was still reduced but 
on a lower level than initially observed (67.59 % and 62.34 % for NTZ and NTZ-R8, 
respectively). Further comparison of groups was not possible because all sham treated mice 











The non-infected mouse showed a villus to crypt ratio of 3:1 and no inflammatory infiltrates in 
the ileal mucosa (Figure 10: A-C). In contrast, all infected mice displayed a qualitatively 
comparable, moderate to severe, subacute, diffuse, proliferative and variably 
lymphohistioplasmacytic ileitis (Figure 10 D-L). The obvious combination of crypt hyperplasia 
and villus atrophy induced a marked drop in the villus to crypt ratio to a median of ≤ 1 in all 
infected mice (Figure 10 D-L). Detached and degenerating epithelial cells, occasionally 
forming crypt abscesses were present within the crypt lumina. There was a trend to more severe 
Figure 9: Average OpG (logarithmic scale) estimated by qPCR over 13 days of observation. 
Mice were infected with 1000 oocysts on study day 0 and treated at 6 dpi. Data shown are mean 





inflammatory infiltrates in the mucosa in the NTZ-R8 treated mice as compared to the NTZ and 
the sham treated mice. Large numbers of C. parvum stages were located at the apical epithelial 
surface. In mice treated with NTZ or NTZ-R8, a trend towards a reduced density of parasites 

















































Figure 10: Histopathological analysis of infected animals after treatment. 
The ileum of non-infected mice (A-C) is shown in comparison to that of Cryptosporidium parvum-
infected mice treated with either DMSO (D-F), NTZ (G-I) or NTZ-R8 (J-L). Arrowhead in E 
showed the degenerating and detached epithelia within the crypt lumina. Arrows represented C. 
parvum at the apical surface epithelium. Bars A, D, G, J = 100 µm; B, E, H, K = 50 µm: C, F, I, L 






Nitazoxanide (NTZ) is the only FDA approved drug for cryptosporidiosis treatment in human. 
However, controversial results regarding efficacy of NTZ in cryptosporidiosis treatment in 
children and HIV patients exist. In particular, NTZ showed limited efficacy in cryptosporidiosis 
treatment in HIV patients in different studies [7, 15 ,16] and  in immunocompromised mice 
[17]. In general, the major obstacle comes from the lack of sufficient efficacy of available drugs 
licensed for treatment of Cryptosporidium infection. As an alternative to efforts aiming at 
developing new drugs, we focused on empowering an existing drug as to render it more 
efficacious. For this purpose, NTZ, an established anti-cryptosporidial drug was coupled to the 
short polycationic cell-penetrating peptide octaarginine to anti-parasitic drugs such as the anti-
malarial experimental drug fosmidomycin dramatically improved drug efficacy to staggering 
40% [10].  
NTZ is a pro- drug that is rapidly hydrolyzed by esterase and transformed into its desacetyl 
dervivative, tizoxanide, the active metabolite [18]. Considering this feature, octaarginine was 
coupled to NTZ in order to release tizoxanide upon esterase cleavage (Figure 3). Octaarginine 
has been demonstrated to cross various biological membranes such as the blood brain barrier 
[19] and membranes of different cell types [9, 20]. Therefore, to evaluate a potential use of 
octaarginine as delivery vehicle for NTZ in Cryptosporidium treatment, we first assessed the 
permeation of octaarginine across parasites membrane as well as cell membranes. The limiting 
factor for a CPP such as octaarginine to function as carrier for any cargos into a cell is the 
permeability across the corresponding biological membrane and it is totally independent of the 
size of cargo [9, 21].  FAM-labelled octaarginine was used to track the permeation of this CPP 
through the parasite and host membranes. We found that octaarginine was taken up more 




explained by the special location of intracellular Cryptosporidium which is extracytoplasmic 
[22]. In fact, although Cryptosporidium species are obligate intracellular parasites, they never 
enter host cytosol but remain throughout their entire intracellular life in an extracytoplasmic 
space directly underneath the host plasma membrane [23]. The parasites are thus protected by 
the host generated membranes of the parasitophorous vacuoles [24] that is a barrier for NTZ to 
cross thus preventing drug accumulation in the parasite sufficient to achieve optimal activity 
on the target. Our findings show that octaarginine penetrates all membranes surrounding the 
parasite in a fast kinetic than the host cell membrane. A strong staining was observed in the 
parasite after less than 30 min incubation while the host cell remained unstained. This results 
suggested that coupling of NTZ to octaarginine represent an attractive alternative to increase 
NTZ accumulation in the parasite.  
Concording with the above-mentioned results on the permeability of the parasite membrane to 
octaarginine, we observed during the in vitro experiments that NTZ coupled with octaarginine 
(NTZ-R8) inhibits the growth of C. parvum in HCT-8 cells more efficiently than NTZ alone 
after 24 h of exposure. The calculated IC50 of NTZ- R8 was 2.9 nM while that of NTZ alone 
was 197 nM. By facilitating the transport of NTZ across the host cell membrane as well as 
through the membrane of the parasite, octaarginine improved the activity of NTZ more than 60-
fold. In our study, NTZ at a dose of 1000 ng/ml inhibits C. parvum replication to 79% that is 
higher than published before [23, 24, 25]. Although NTZ can be dissolved in DMSO, we 
recognized that precipitation occurred after further dilution in DMEM culture medium. 
Therefore, we applied sonication for 30 s (2-3 times) to ensure complete dissolution in the 
medium before adding to infected cells. It may be assumed that this additional procedure 
increased the activity of NTZ to a level higher than in former studies.  
Although many drugs have been shown to successfully inhibit Cryptosporidium in vitro, e.g. 




obvious [16]. There are many elements such as bioavailability, pharmacokinetics, food-drug 
interaction [28] which influence the efficacy in animals and that partly explain the difficult 
transferability of in vitro results to in vivo conditions [29].  
In order to further investigate the effect of NTZ-R8, we decided to assess the conjugate 
molecule in an animal model. For this purpose, IFN-γ knockout mice were used because they 
are generally considered highly susceptible to C. parvum [17, 29, 30] and suitably mimic the 
response of immunocompromised patients to this parasite. Other mouse models such as SCID 
[31], neonate mice with infection doses from 1x103 to 2.5x104 oocysts [32,33,34], or 
dexamethasone-treated mice [35] require high infection dose (i.e 106 oocysts), while IFN-γ- 
knockout mice may display severe illness after inoculation of only 10 oocysts [30]. IFN-γ- 
knockout mice have been used to analyze the impact of drug therapy on acute infection [36]. 
The titration results showed that regardless of how many oocysts (1000, 5000 or even 10000 
oocysts) were used for infection, the peak of infection was recorded at 8 dpi. The severity of 
sickness was independent on the number of inoculated oocysts. However, the main difference 
among 3 groups was the prepatency. Infection with the highest dose 10000 oocysts resulted in 
patency at 1 dpi while the earliest excretion was observed on 2 dpi in infected mice with lower 
infection dose of 5000 or 1000 oocysts. Therefore, to reduce unnecessary suffer for mice, lowest 
tested dose of 1000 oocysts was applied in further in vivo experiments. This inoculation dose 
was lethal (reaching humane endpoints or animals dead) between 8 to 14 dpi [36]. Basing on 
the development of clinical symptoms of infected mouse with Cryptosporidium in our trial 
experiment as well as previous study described by Manjunatha [17], the treatment was applied 
on 6 dpi to evaluate the drug efficacy. In general, the typical clinical symptoms of 
cryptosporidiosis such as emaciation, anorexia, dehydration, ruffled fur, and a high level of 
oocyst excretion were recorded as previously described in mouse models. The most profound 




however the development of diarrhea was not obvious in the current mouse experiment which 
is a general limitation of mouse models [40]. Consequently, it was not possible to evaluate the 
efficacy of the applied treatment on this clinical parameter. This confirms that results obtained 
in laboratory rodent models in terms of cryptosporidiosis control have to be interpreted with 
caution. Since the increased survival in the treated groups was neither accompanied by a 
decrease in the amount of oocysts shed in the feces, nor a marked drop in the density of parasites 
in the mucosa, further studies concerning the mechanism of action of NTZ and NTZ-R8 in vivo 
are highly needed. In general, the IFN-γ -knockout mouse model is considered appropriate for 
pre-clinical testing of anti-cryptosporidial drugs, however, it is essential to further evaluate the 
efficacy of NTZ-R8 in the natural host, e.g. neonate calves.  
Unfortunately, the synthetic conjugate NTZ-R8 is not easily affordable. Consequently, the 
conjugate drug was only available in limited amounts and the test was performed at a rather 
low concentration of 2 mg/kg BW. For NTZ the regular dose would be 100-200 mg/kg BW 
[17, 23], but it was decided to apply a reduced treatment dose of NTZ 10 mg/kg BW  to allow 
better comparison of NTZ-R8 and NTZ. We expected failure of the low dose NTZ treatment 
since even at a dose of 100 mg/kg BW, NTZ  was demonstrated to fail in controlling the parasite 
infection [17]. However, the results obtained in the current study show in that high efficacy in 
decreasing oocysts excretion is achieved 24 h after treatment with a similar reduction by  NTZ 
(96%) and  NTZ-R8 (94%). Thereafter, the oocyst excretion was not that much reduced with 
oocyst counts averaging 60% of the values recorded for the sham treatment.  A clear difference 
in terms of clinical health was seen in mice treated with NTZ-R8. Around 80% of mice treated 
with NTZ-R8 survived whereas this was the case for only 40% of NTZ treated mice, although 
it is not significant (P > 0.05). Although the treatment dose of NTZ-R8 was only 2 mg/kg BW, 
it demonstrated clinical efficacy even higher than that of a 5-fold dose of NTZ alone to avoid 




It remains to be shown whether a dose-response relationship exists and whether a higher 
treatment dose of NTZ-R8 will result in even better efficacy or, on the contrary, higher toxicity. 
Whatsoever, it was observed that C. parvum induced weight loss was interrupted in surviving 
treated mice and weight even slightly increased at 12 dpi or 13 dpi in the NTZ-R8 group. 
Recovery of mucosal tissue required more time than expected, and the observation period 
should be extended in further studies to e.g. 21 dpi to evaluate how long it takes until complete 
regeneration is obtained in NTZ-R8 treated animals. 
Altogether, octaarginine proved its suitability as drug delivery vehicle in cryptosporidiosis 
treatment in in vitro and in vivo studies. As a cell-penetrating peptide (CPP) octaarginine 
facilitates the uptake of NTZ even into intracellular parasite stages shielded by the membrane 
of the parasitophorous vacuole.  This improves the efficacy of NTZ and probably reduces 
toxicity through dose reduction. Based on these findings, further studies should be encouraged 
including evaluation of NTZ-R8 in target species.   
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4. Comprehensive discussion 
4.1 Developing a novel octaarginine-based transfection method for 
Cryptosporidium parvum 
In general, transfection methods can be classified into two groups: viral and non-viral transfection 
(including physical or chemical). Every method has its advantages and disadvantages. For instance, the 
viral transfection is based on the ability of a virus to integrate into the host genome. Thus, the 
transfection efficiency is quite high using respective methods. However, the viral-mediated transfection 
causes cytotoxicity and is subject to immunogenicity issues (KIM and EBERWINE 2010). To avoid 
this, the non-viral transfection is either based on electroporation or on the utilization of polycationic 
polymer commonly used than the viral transfection to introduce foreign genes into the host cells. Cell-
penetrating peptides (CPPs) such as octaarginine are well-known for their intrinsic property to penetrate 
almost all known biological membranes and even the blood-brain barrier (GUIDOTTI et al. 2017). 
Strikingly, the ability of CPPs to deliver cargo across biological membranes does not depend on the size 
of the molecule to be transported but rather on the permeability of the membrane to the CPPs alone 
(KAMENA et al. 2011). Octaarginine was shown to penetrate almost all tested biological membranes 
with only few exceptions such as the membranes of non-infected red blood cells and the parasitophorous 
vacuole membrane of Toxoplasma gondii (KAMENA et al. 2008, SPARR et al. 2013). No respective 
information has been published before with respect to C. parvum.  
In the current project, the intact oocyst wall of C. parvum was shown to be impermeable to octaarginine. 
When FAM-octaarginine was incubated with intact oocysts, short-time excysted (STE) oocysts, freshly 
excysted sporozoites and infected host cells, it was observed that the peptide can only stain the wall of 
intact oocysts without penetrating inside oocysts. This is probably due to the complex trilaminar 
structure of the Cryptosporidium oocyst wall. The very rigid oocyst wall makes Cryptosporidium 
oocysts resistant to harsh environmental conditions and to many chemical disinfection protocols 
(LENDNER and DAUGSCHIES, 2014). However, octaarginine easily penetrated into the STE oocysts, 
sporozoites and even into intracellular stages where the parasite is embedded in the parasitophorous 
vacuole. The kinetics of FAM-octaarginine uptake depends on the biological membranes. For example, 
the uptake by STE oocysts and sporozoites occurred within 30 minutes, which was much faster 
compared to the uptake by intracellular stages (trophozoites and meronts) which took around one hour. 
These findings encouraged the evaluation of perspectives for a new transfection method within 
comparison to electroporation, less aggressive transfection protocol. Another point of interest was 





Although CPPs transport other molecules across cell membranes without displaying relevant toxicity, 
their ability to carry DNA for transfection is very poor (JEONG et al. 2016). This can be explained by 
the unstable linear structure, or the short length of the peptide which is not sufficient for plasmid 
condensation (KILK et al. 2005). Therefore, CPPs have been modified by conjugating them with 
different chemical substances such as polyallylamine, poly-L-lysine, polyethylenimine (PEI) that show 
better plasmid condensation properties (SABOURI-RAD et al. 2017). Specifically, PEI shows excellent 
plasmid condensation properties, and high efficiency in gene delivery (FISCHER et al. 1999, 
NEUBERG and KICHLER 2014, ZHOU et al. 2018). By forming the proton sponge, PEI protects 
foreign DNA from lysosomal degradation and results in increasing transfected gene expression 
(THOMAS et al. 2019). However, PEI is also known to induce high cytotoxicity and to decrease cellular 
metabolic activities (FLOREA et al. 2002, GODBEY et al. 2001).  
Interestingly, the combination of PEI and CPPs does not only significantly reduce cytotoxicity of PEI 
but also increases gene delivery efficiency (MUNYENDO et al. 2012). This observation prompted us 
to consider the combination of PEI and octaarginine for transfection of C. parvum. In order to identify 
the appropriate concentration of PEI to be used for the transfection, a gel retardation assay was 
conducted. The gel retardation can help to establish the optimal ratio of PEI/plasmid complex. It is 
characterized by the N/P ratio in which N is the number of amino groups positively charged and P is the 
number of phosphate groups negatively charged. It was observed that the entire plasmid was completely 
condensed at the N/P ratio of 12 and above (PUBLICATION 1). Interestingly, with the addition of 
octaarginine to the PEI/plasmid complex, the optimal N/P ratio was seen at a lower value of 10, which 
indicates that octaarginine might also contribute to DNA condensation. This result supported the 
assumption that combining PEI and octaarginine may enhance transfection of C. parvum. Consequently, 
the complex of DNA/PEI/octaarginine was used for transfection of freshly excysted sporozoites, STE 
oocysts, or intact oocysts (see Figure. 3 and Figure. 4). Successful transfection was only found when 
freshly excysted sporozoites or STE oocysts were used while transfection failed when intact oocysts 
were used. These results demonstrate that during excystation the permeability of the parasite stages 
increases resulting in higher susceptibility to transfection in the presence of octaarginine, highlighting 
































Incubation with FAM-octaarginine at 37 oC for 30 min to 1h in infection medium 
C. pavrum oocysts 
NaOCl 5.25%/PBS (ratio 1:1) 
Incubation on ice for 5 min  
Oocysts 
 
Incubation oocysts in sterile excystation medium at 15 oC for 1h 
Incubation at 37 oC for 
15 min 
Incubation at 37 oC 
for 3h 





Immunoflourescent assay (IFA) 
Short time excysted 
oocysts 
 
Laser scanning confocal microscopy 
Excystation medium: NaT 
0.8% in DMEM 2% FCS, 
1% Amphotericin B and 
1% Penicillin/Streptomycin 
Infection medium: DMEM 
2% FCS, 1% 1% 
Amphotericine B and 1% 
Penicillin/ Streptomycin 
 
Figure 3: Analysis of permeation of FAM-octaarginine into intact oocysts, STE oocysts and 
sporozoites, intracelluar stages of C.parvum  
Incubation with 
host cells for 24h 




























DNA condensation  
Gel retardation assay to define the 
optimal ratio N/P for transfection 
DNA plasmid (GFP as reporter 
gene) + PEI + octaarginine with N/P 
>10, vortex 
Incubation at 37 oC for at least 30 
min to 1 hour 
Oocysts, STE oocysts, or 
sporozoites 
DNA/PEI/octaarginine  
Incubation at 37 oC for 1 h 
Growing of HCT-8 monolayers (70-80%) confluence and observing the express of GFP 
protein in 24 h to 48 h of incubation 
Immunofluorecent assay (IFA) and laser scanning confocal microscopy 
Figure 4: Summary of the transfection protocol for C. parvum using DNA/PEI/octaarginine 
The principle of DNA condensation is based on 















Interestingly, the transfection with STE oocysts yielded a higher amount of transgenic parasites in 
comparison to freshly excysted sporozoites where transgenic parasites could be rarely found. In spite of 
many attempts to increase transfection efficiency for excysted sporozoites, successful transfection was 
only occasionally achieve. Although long time incubation did not impair the survival of sporozoites in 
terms of continuing motility and integrity of morphology, it seemed to dramatically reduce the ability 
of the parasites to infect host cells, and thus obviously altered viability. The reason for higher 
susceptibility to transfection of oocysts that were exposed to excystation only for a short time (“STE 
oocysts”) in comparison to fully excysted sporozoites appears unclear so far and remains to be further 
investigated. 
The new transfection protocol based on PEI and octaarginine presents several advantages compared to 
conventional electroporation. First, it requires a lower amount of DNA (1-5µg) than the electroporation 
protocol (40 µg) (POTTER and HELLER 2003). Secondly, the principle of electroporation is based on 
introducing a high voltage electric shock to leak the cell membrane thus enabling transfer of foreign 
DNA into host cells. With that process, a large number of parasites are insulted and even killed, thus it 
limits the yield of alive transfected organisms. Therefore, electroporation-based approaches require a 
high number of parasites of around 1x107 (PAWLOWIC et al. 2017). With the new method reported 
here 50 times less parasites 2x105 are required. However, transfection with either PEI and plasmid or 
octaarginine and plasmid alone did not yield any GFP expressing parasites (data not shown). Thus it is 
obvious that PEI and octaarginine are both essential components in the combination used for the newly 
developed transfection protocol. In the current study, the non-covalent conjugation was applied to 
combine octaarginine and PEI by mixing to form the desired chemical complex. The non-covalent 
conjugation method has been widely applied in previous studies, e.g. on the interaction between avidin 
and biotin (WIERZBICKI et al. 2014).  A major advantage of the non-covalent method is that it is easy 
to perform without requiring any special chemicals, and is thus easily accessible for research. 
Altogether, the PEI/octaarginine- based transfection method is a highly suitable method for 
Cryptosporidium transfection requiring only small amounts of DNA and achievable numbers of 
parasites, and is simple to perform.  
4.2 Octaarginine as a vehicle for nitazoxanide (NTZ) delivery  
Although cryptosporidiosis has been recognized as an important public health problem causing 
morbidity and mortality not only in animals but also in man, there is a lack of effective treatment options 
in any host species. Vaccines are not available so far. Halofuginone is a licensed drug for prevention 
and treatment of cryptosporidiosis in calves in Europe (KEIDEL and DAUGSCHIES 2013). In man, 
NTZ [2-acetyloxy-N-(5-nitro-2-thiazolyl) benzamide] is currently the only drug approved by FDA for 




to persons being under particular risk such as immunocompromised people and malnourished children 
(CABADA and WHITE 2010, MEAD and ARROWOOD 2014). Disappointing results were also 
obtained by in vivo testing in immunocompromised mice (MANJUNATHA et al. 2017). Therefore, 
there is a pressing need for developing novel and efficient treatments and hopefully vaccines. Recently, 
several potential drug candidates for Cryptosporidium treatment were tested in vitro and in vivo such as 
CDPK1 inhibitor (LENDNER et al. 2014), oleyphosphocholine (SONZOGNI-DESAUTELS et al. 
2015), bumped kinase inhibitor (SCHAEFER et al. 2016), PI (4) inhibitor (MANJUNATHA et al. 2017), 
clofazimine (LOVE et al. 2017), and benzoxaborole (LUNDE et al. 2019). However, the procedure for 
approving a new drug is cumbersome, costly and takes a long time. Alternative, other approaches such 
as drug repurposing or empowering of available drugs could be applied to achieve suitable treatment 
options in due course. One of the most crucial factors influencing the development of novel drugs is the 
delivery efficiency (FOGED and NIELSEN 2008). The host plasma membrane of the PV is the barrier 
that hinders the translocation of chemical substances to the site of C. parvum infestation (ZHANG et al. 
2019). The host cell membrane protects the entire cell and regulates e.g. nutrient transport and metabolite 
excretion. Likewise, it also prevents the uptake of pharmaceutics and especially hydrophilic drug 
molecules (RAUTIO et al. 2008). 
NTZ is classified into the class IV group which is characterized by low solubility and low permeation 
across the membranes according to the Biopharmaceutical Classification System (FIRAKE et al. 2017). 
Due to the low solubility, NTZ has low bioavailability and it therefore, requires high doses to achieve 
sufficient efficacy (FÉLIX-SONDA et al. 2014). Most importantly, the balance between the efficacy at 
high dosage and related cytotoxicity requires attention. The general strategy to overcome  solubility 
limitations is the generation of novel solid phases such as amorphous forms, solvates, salts or cocrystals 
(GADADE and PEKAMWAR 2016). In the current study, we have opted to enhance the permeability 
of cell membranes to NTZ by linking it to the CPP octaarginine.   
CPPs have been widely applied in pharmaceutics and examined for their capacity to overcome the 
plasma membrane barrier and other biological membranes without any indication of cytotoxicity 
(BECHARA and SAGAN 2013; DINCA et al. 2016). In the current study, NTZ was coupled to 
octaarginine to deliver NTZ to the intracellular site of parasite location. The results presented in 
PUBLICATION 1 and MANUSCRIPT 2 demonstrate the high permeability of Cryptosporidium 
membranes to octaarginine. In previous studies by SPARR et al. (2013), it was shown that coupling of 
the anti-malaria drug fosmidomycine to octaarginine considerably enhances the uptake of the drug and 
hence its efficacy for more than 40-fold as compared to fosmidomycine alone. This study also points 
out that octaarginine is harmless to host cells. Those results encouraged the hypothesis that higher 




NTZ was chosen for two reasons. Firstly, this is the only approved drug for cryptosporidiosis treatment 
in humans. Secondly, the chemical structure of NTZ is ideally suited for a reversible coupling to 
octaarginine. In general, the stability of CPPs and the capacity of the liberation of cargo are two major 
concerns related to applying CPPs for the delivery of pharmaceutics. NTZ is a pro-drug that is activated 
by esterase inside the cells to generate the active molecule tizoxanide (FOX and SARAVOLATZ 2005). 
This offers the option to couple octaarginine to the labile ester function of NTZ as an esterase- releasable 
moiety (Figure 5). Normally, natural peptides are rapidly degraded when exposed to intestinal enzymes 
(KRISTENSEN et al. 2016). However, using a synthetic non-natural β-octaarginine derivative renders 
the peptide resistant to peptidase. 
 
 
Testing anti-cryptosporidial candidate compounds in vitro is a crucial step in drug development. To 
perform in vitro testing on C. parvum intracellular stages, these have to be cultured in appropriate cell 
lines that originate from animal or human tissues. Attempts to apply axenic cultures did not result in 
success in terms of appropriate screening models. Particularly, the human ileocecal adenocarcinoma 
(HCT-8) cell line has been widely used in Cryptosporidium research. Up to now, many read-outs for 
evaluation of in vitro results have been reported, including microscopic counting of parasitic stages, 
enzyme-linked immunosorbent assay, chemiluminescence immunoassay (YOU et al. 1996), real-time 
quantitative PCR (SHAHIDUZZAMAN et al. 2009), or quantification of transgenic parasites expressing 
luciferase (VINAYAK et al. 2015). At present, measuring DNA of parasites by quantitative PCR is 
widely used because of high accuracy and convenience. The study of CAI et al. (2005) pointed out that 
under in vitro conditions, the decay of DNA of dead parasites (99% in 24 h to 48 h) took longer than 
that of RNA (99% in 3 h). Hence, the level of RNA was considered to better represent for live parasites 
than DNA assessment. In fact, the level of 18sRNA transcribed by parasites  after exposure to anti-
Figure 5: The chemical structures of tizoxanide, nitazoxanide (NTZ) and nitazoxanide-
octaarginine (NTZ-R8). Red arrow showing the cleavage position by esterase to release 
tizoxanide from NTZ-R8 




cryptosporidial treatment allowed to detect only living parasites (CAI et al. 2005, ZHANG and ZHU 
2015) and prevented errors in undermining drug efficacy. 18sRNA of host cells was applied for 
normalization. The advantage of the reverse-transcriptase PCR method is higher accuracy compared to 
quantitative PCR. However, the method bears a disadvantage since RNA is not as stable as DNA and 
thus the quantification may easily lead to false negative results.  
The combination of NTZ and octaarginine (NTZ-R8) was tested for cytotoxicity before assessment of 
in vitro inhibition of C. parvum.  According to ISO 10993-5, cell viability of more than 80% is 
considered to reflect non-cytotoxicity. In the current study, cell viability of cultures exposed to the 
highest concentration of NTZ (25 µg/ml) and octaarginine (100 µg/ml) was 85% and 99%; respectively. 
Thus, the used concentrations were all in the range of non-cytotoxicity. These results were compatible 
to those obtained by SHARMA et al. (2014). Serial dilutions of NTZ and NTZ-R8 (1000, 100, 50, 10, 
5, 1 ng/ml) were tested in a growth inhibition assay of C. parvum. The results reported in 
MANUSCRIPT 2 demonstrate that NTZ coupled to octaarginine (NTZ-R8) dramatically improved the 
growth inhibition of C. parvum within 24 h post exposure. The IC50 value was 60.54 ng/ml (197 nM) 
for uncoupled NTZ while IC50 of NTZ-R8 was much lower with only 4.499 ng/ml (2.9 nM). As 
expected, octaarginine supported passage of other molecules through cell membranes, and NTZ coupled 
with octaarginine easily penetrated into the parasite, even when the parasites were located in the 
parasitophorous vacuole. In summary, the aim to achieve improved the inhibition of the parasite was 
perfectly reached under in vitro conditions. 
In current study, 1000 ng/ml of NTZ inhibited C. parvum development by 79%, and thus anti-
cryptosporidial efficacy was seen at a far higher than reported in previous publications (GRIFFITHS et 
al. 1998, CAI et al. 2005, SHARMA et al. 2014). In general, NTZ has a low aqueous solubility (7.5 
ng/ml) (SALAS-ZÚÑIGA et al. 2020). Therefore, choosing an appropriate solvent for NTZ is very 
crucial for in vitro studies. Although NTZ dissolves in DMSO, precipitation was observed when NTZ 
was further diluted in culture medium DMEM. To tackle this problem, a short exposure of NTZ in 
DMEM to sonication for 30 seconds (2-3 times) appeared to be a suitable procedure to increase 
solubility. The sonication was applied to dissolve both NTZ and NTZ-R8. Both the developed protocol 
to increase solubility and the highly sensitive evaluation method (RT-qPCR) may explain why the IC50 
observed for NTZ was lower in the current evaluation than in previous studies.  
Several anticoccidial drugs were shown before to control Cryptosporidium under in vitro conditions 
(SHAHIDUZZAMAN et al. 2009, SHARMA et al. 2014). However, only few compounds such as 
halofuginone and PRM present a partial inhibitory activity on Cryptosporidium infection in animal 
models (MEAD and ARROWOOD 2014). There are many elements such as bioavailability, 




difficulties in concluding on efficacy of a drug based on  in vitro testing only  (SONZOGNI-
DESAUTELS et al. 2015).  
To perform in vivo drug testing for Cryptosporidium infection, it is crucial to choose an appropriate 
animal model. In the current study, the IFN-γ -knockout mouse model was used because it is considered 
to be highly susceptible  to  cryptosporidiosis (OETTINGEN et al. 2008, SONZOGNI-DESAUTELS et 
al. 2015) and to at least partly mimic the response of immunocompromised patients to infection with 
Cryptosporidium. Other mouse models such as dexamethasone-treated mice (RASMUSSEN and 
HEALEY 1992), severe combined immunodeficiency (SCID) mice (TZIPORI et al. 1995), neonate mice 
(DOWNEY et al. 2008, DELAUNAY et al. 2000) were also applied with more or less success. However, 
all of these mouse models required a high amount of oocysts ranging from 105 _ 106 per animal for 
infection.  In contrast, C57BL/6 IFN-γ- knockout mice display severe illness following inoculation of  
only 10 oocysts (OETTINGEN et al. 2008). Furthermore,  IFN-γ- knockout mice can be suitable for 
analyzing the efficacy of drug therapy on acute infection at the reasonable infection doses (YOU and 
MEAD 1998, GRIFFITHS et al. 1998, SONZOGNI-DESAUTELS et al. 2015). Therefore, such mice 
were assumed ideal to confirm the promising in vitro data on the anti-cryptosporidial properties of NTZ-
R8 in a laboratory animal model. Altogether, the IFN-γ- knockout mouse model is considered 
appropriate for pre-clinical testing of anti-cryptosporidial drugs. 
The infection doses tested in the current experiments (MANUSCRIPT 2) were 1000, 5000, and 10000 
oocysts per mouse. Regardless of how many oocysts were used for the infection, the peak of infection 
was recorded at 8 dpi. However, the prepatency differed between the groups of mice. Infection with 
10000 oocysts resulted in patency starting 1 dpi while the earliest excretion was seen on 2 dpi in mice 
infected with lower infection dose of 1000 or 5000 oocysts. The severity of sickness did not depend on 
the number of inoculated oocysts. Our findings was compatible with the results from of GRIFFITHS et 
al. (1998) obtained in the INF-γ knock mouse model, and also of data obtained in other mouse models 
(YANG et al. 2000, ZHENG 2020). Consequently, the infection dose of 1000 oocysts was deemed 
sufficient and chosen for further in vivo trials.  This inoculation dose was described to be lethal to mice 
between 8 dpi and day 14 dpi (YOU and MEAD 1998). Therefore, it was decided to treat infected mice 
at 6 dpi order to assess protection achieved by treatment in terms of clinical disease. In fact, typical 
clinical symptoms of cryptosporidiosis such as weight loss, anorexia, dehydration, and ruffled fur were 
observed and considerable oocyst excretion was seen in infected IFN-γ knockout mice. The 
histopathological examination revealed typical pathogenic lesions as villous atrophy, crypt hyperplasia 
and degenerating epithelial cells within the crypt lumina. However, the most typical symptom of 
cryptosporidiosis in infected neonate calves (KEIDEL and DAUGSCHIES 2013, THOMSON et al. 
2017, AYDOGDU et al. 2018) and in humans (DAVIES and CHALMERS 2009, REHN et al. 2015) is 




reported as one of the drawbacks of mouse models in cryptosporidiosis research (GRIFFITHS et al. 
1998). Consequently, we could not demonstrate efficacy of NTZ or NTZ-R8 on C. parvum induced 
diarrhoea. However, since cryptosporidiosis was well controlled by NTZ-R8, it appears highly probable 
that a distinct effect on diarrhoea will be seen if NTZ-R8 is applied in the target species. This assumption 
has to be investigated in future studies.  
Because of the very high expense associated with the chemical synthesis of NTZ-R8, only treatment of 
one group with a low concentration of 2 mg/kg BW could be tested in this study. Since it was expected 
that coupling to octaarginine would dramatically increase NTZ efficacy, we decided to compare 
treatment efficacy to that of a five-fold higher dose of NTZ (10 mg/kg BW) alone. In other studies, a 
much higher dose of NTZ of 100-200 mg/kg BW was used in mice (THEODOS et al. 1998, 
MANJUNATHA et al. 2017).  Even a very high NTZ dose as 100 mg/kg BW showed only modest 
efficacy on the parasite (MANJUNATHA et al. 2017). Therefore, it was expected that a low dose of 10 
mg/kg BW might fail to prevent disease as in fact observed in the experiment. Inclusion of an additional 
sham treatment group with an even lower dose of such as 2 mg/kg BW (the dose used for NTZ-R8) 
would most probably have caused additional and serve animal suffering without contributing to 
extension of knowledge.  
The results of oocysts shedding obtained in current study showed that high efficacy in reducing number 
of oocysts was observed after 24 h treatment with a similar reduction by 10 mg/kg BW NTZ (96%) and 
2 mg/kg BW NTZ-R8 (94%).  Thereafter, OpG values were reduced to around 60% in both treatment 
groups as compared to sham treatment. However, the survival rate and general health conditions (smooth 
fur, activity, posture, and capacity to response) of mice in both treated groups were generally superior 
compared to the sham treated mice. The latter displayed ruffled fur, trembling and delayed response to 
stimulation at 9 dpi. Altogether, both NTZ and NTZ-R8 dramatically enhanced performance of infected 
mice. While all infected mice in the shame treated group died at 11 dpi, treated mice survived until the 
end of the experiment. Remarkably, NTZ-R8, although given at a low treatment dose of only 2 mg/ kg 
BW, displayed a higher efficacy than NTZ alone at 5-fold higher dose (10 mg/kg BW) by allowing 
survival of 80% of the respective mice in comparison with 40% of mice that were treated with NTZ 
only. Thus, octaarginine improved dramatically the efficacy of NTZ treatment of Cryptosporidium 
infection, especially in terms of survival while OpG values were less affected. 
Although the current study demonstrates the suitability of octaarginine as a vehicle to deliver NTZ 
across membranes and thus opens new options to improve Cryptosporidium treatment, further 
investigations are necessary. For instance, dose titration studies in further laboratory rodent experiments 
are pivotal to define the most appropriate dose of NTZ-R8. Besides that, the length of infection 




treatment on cryptosporidiosis, e.g. in terms of weight development or histopathological alterations of 
the ileum. 
 It is obvious that immunodeficient mice are a rather artificial model. Results obtained from respective 
studies are though important in terms of pre-clinical screening, to validate in vitro findings and to 
construct and evaluate theoretical considerations. However, this does not replace experiments in natural 
hosts such as calves for C. parvum. In fact, the suitability of NTZ-R8 clearly remains to be demonstrated 
in the target species and cannot be postulated based on the current in vitro and in vivo data obtained 
from laboratory rodent experiment alone. Moreover, aspects like toxicity, pharmacodynamics and side 
effects have to be addressed, particularly if NTZ-R8 is considered as a drug for use in livestock or in 
humans.  
5. Conclusion 
The combination of octaarginine and PEI- two polycatonic molecules well suited for the delivery of 
plasmid DNA into Cryptosporidium. It is important to note that successful transfection depends on the 
permeability of the parasite membrane to octaarginine albeit not exclusively, since free sporozoites were 
poorly transfected although they show the highest permeability to octaarginine. A limitation of using 
sporozoites in transfection is probably rapid loss their infectivity during various incubation steps. In 
contrast, short time excystation (STE) oocysts yield the best results because in addition to being 
permeable to octaargine and sporozoites of STE oocysts are exposed to excystation and transfection 
medium for a short period rendering them more vital than fully excysted oocysts. The major advantages 
of our novel transfection protocol are that it requires a very low amount of plasmid DNA is simple to 
perform and does not require any sophisticated equipment. In addition, the capacity of octaarginine to 
function as drug delivery vehicle in Cryptosporidium treatment was also clearly established. Coupling 
of NTZ to octaarginine (NTZ-R8) dramatically improved treatment efficacy at a distinctly reduced dose 
of the active ingredient. These findings usher in new paths for treatment of Cryptosporidium infection 
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Introduction: Cryptosporidium parvum is one of the most common causes of diarrhea worldwide in 
neonatal calves. This pathogen is also life-threatening in malnourished children and immunodeficient 
patients. There is no vaccine and a single drug nitazoxanide (NTZ), of only the moderate efficacy has 
been approved by FDA for cryptosporidiosis treatment in human. Octaarginine is known to facilitate the 
transport of other molecules across cell membranes and has been use to transfect protozoan organisms. 
It is also proposed to increase the efficacy of drugs against intracellular pathogens. 
Aims of the study: The capacity of octaarginine to support transfection of C. parvum as an alternative 
to electroporation was evaluated. Furthermore, it was studied whether octaarginine covalently bound to 
NTZ (NTZ-R8) improves efficacy against the parasite.  
Animals, materials and methods: FAM-octaarginine was added to either intact oocysts, short-time 
excystation exposed (STE) oocysts, excysted sporozoites, intracellular stages of C. parvum to assess the 
permeability of the Cryptosporidium membrane to the peptide. The optimal conditions for condensation 
of plasmid for transfection experiments were evaluated by testing different N/P ratios applying by gel 
retardation assay. The transfection complex octaarginine/polyethyleneimine (PEI)/DNA was also 
incubated with intact oocysts, STE oocysts, and excysted sporozoites. Transfected parasites were 
transferred to HCT-8 cell cultures and further incubated for 24 h. Immunoflourescence assay (IFA) was 
performed to detect successfully transfected parasites. To evaluate the suitability of octaarginine as a 
vehicle supporting transport of NTZ across membranes, octaarginine was coupled to NTZ to produce 
NTZ-R8. Cryptosporidium oocysts were inoculated into HCT-8 cell monolayers in the presence of NTZ 
and NTZ-R8 at concentrations of 1, 5, 10, 50, 100 or 1000 ng/ml. Parasite growth was monitored by 
RT- qPCR after RNA extraction from C. parvum exposed HTC-8 cell cultures. RT-qPCR was performed 
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on the target gene 18S rRNA of Cryptosporidium and normalized to the expression of the housekeeping 
gene 18S rRNA of host cells. To evaluate the efficacy of NTZ-R8 in vivo, IFN-γ knockout mice were 
orally inoculated with 1000 oocysts each, except for the non-infected controls. Infected mice were 
treated with NTZ (10 mg/kg BW) or NTZ-R8 (2 mg/kg BW) in 7 days. The efficacy of treatment was 
evaluated by oocyst excretion, survival rate, clinical symptoms, and histopathological changes in the 
ileum.  
Results: Octaarginine easily penetrated into Cryptosporidium sporozoites and STE oocysts, and 
intracellular stages while the membrane of intact oocysts remained impermeable. The optimal N/P ratio 
for the full DNA plasmid condensation starts from 10 when octaarginine was also added to the complex. 
Successful transfection of excysted sporozoites and STE oocysts was observed with only 1µg plasmid 
in the transfection complex. Transfection was not achieve when intact oocysts were used. The half-
maximal inhibition concentration (IC50) of NTZ and NTZ-R8 was 60.54 ng/ml (197 nM) and 4.499 
ng/ml (2.9 nM), respectively. Therefore, octaarginine significantly improved inhibition C. parvum 
growth by NTZ around 68 times (P < 0.05). During in vivo studies, it was observed that infected mice 
displayed symptoms of cryptosporidiosis such as anorexia, weight loss and ruffled fur. Mice treated with 
NTZ at 10 mg/kg BW displayed in 40% survival while mice treated with NTZ-R8 at 2 mg/ kg BW 
showed a distinctly higher survival rate of 80%, albeit non- significant (P > 0.05).  
Conclusion: DNA condensation by PEI and DNA delivery by octaarginine allows simple and rapid 
transfection that requires a small amount of plasmid DNA only and does not depend on sophisticated 
equipment. Best results were obtained using STE oocysts. Octaarginine also successfully transported 
the anticryptosporidial compound NTZ into extracellular and intracellular stages of C. parvum and is 
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Einleitung: Cryptosporidium parvum ist weltweit eine der häufigsten Ursachen für 
Durchfallerkrankungen bei neugeborenen Kälbern. Auch für unterernährte Kinder und 
immungeschwächte Patienten ist dieser Erreger lebensbedrohlich. Es gibt keinen Impfstoff, und ein 
einziges Medikament von mäßiger Wirksamkeit, Nitazoxanid (NTZ),  wurde von der FDA für die 
Kryptosporidiose-Behandlung beim Menschen zugelassen. Octaarginin erleichtert den Transport von 
Molekülen durch Zellmembranen und kann zur Transfektion von Protozoen verwendet werden. Es wird 
vermutet, dass es auch die Wirksamkeit von Medikamenten gegen intrazelluläre Krankheitserreger 
erhöhen kann. 
Ziele der Untersuchungen: Die Eignung von Octaarginin, C. parvum zu transfizieren wurde als 
Alternative zur Transfektion mittels Elektroporation untersucht. Darüber hinaus wurde getestet, ob 
kovalent an NTZ gebundenes Octaarginin dessen Wirksamkeit gegen den Parasiten steigert. 
Tiere, Material und Methoden: FAM-markiertes Octaarginin wurde entweder intakten Oozysten, teil- 
exzystierten (STE) Oozysten, exzystierten Sporozoiten, oder intrazelluläre Stadien von C. parvum 
zugesetzt, um die Permeabilität der Kryptosporidienmembran für das Peptid zu bewerten. Die optimalen 
Bedingungen für die Plasmidkondensation  zur Transfektion wurden durch Testen verschiedener N/P-
Verhältnisse untersucht und durch einen Gelretardierungstest festgelegt. Der Transfektionskomplex 
wurde mit intakten Oozysten, STE-Oozysten und exzystierten Sporozoiten inkubiert. Transfizierte 
Parasiten wurden auf HCT-8-Zellkulturen übertragen und 24 h weiter inkubiert. Zum Nachweis 
erfolgreich transfizierter Parasiten wurde ein Immunfluoreszenztest (IFA) durchgeführt. Um die 
Eignung von Octaarginin als Vehikel für den Transport von NTZ über Zellmembranen zu analysieren, 
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wurde NTZ-R8 durch Koppelung von Octaarginin an NTZ produziert. Cryptosporidium-Oozysten 
wurden auf HCT-8-Zell-Monolayern in Gegenwart von NTZ und NTZ-R8 in Konzentrationen von 1 bis 
1000 ng/ml) gegeben. Das Parasitenwachstum wurde mittels RT-qPCR nach RNA-Extraktion aus C. 
parvum-exponierten HTC-8-Zellkulturen anhand des C. parvum Zielgens 18S rRNA durchgeführt. Die 
Expression des 18S rRNA-Gens der Wirtszellen diente der Normalisierung. Um die Wirksamkeit von 
NTZ-R8 in vivo zu bewerten, wurden IFN-γ Knockout-Mäuse oral mit jeweils 1000 Oozysten infiziert. 
Die Mäuse wurden 7 Tage post infectionem (dpi) mit NTZ-R8 (2 mg/kg KGW) oder NTZ in einer 
fünffach höheren Dosis (10 mg/kg KGW) behandelt. Die Wirksamkeit der Behandlung wurde 
vergleichend anhand der Oozystenausscheidung, der Überlebensrate, der klinischen Symptome und 
histopathologischer Befunde im Ileum bewertet.  
Ergebnisse: Über die FAM-Markierung konnte dargestellt werden, dass Octaarginin leicht in 
Cryptosporidium-Sporozoiten und STE-Oozysten sowie in intrazelluläre Stadien des Erregers eindringt, 
während die Wand intakter Oozysten völlig undurchlässig ist. Das optimale N/P-Verhältnis für die 
vollständige DNA-Plasmidkondensation liegt in Anwesenheit von Octaarginin bei einem Wert von 10. 
Eine erfolgreiche Transfektion von exzystierten Sporozoiten und STE-Oozysten wurde mit nur 1 µg 
Plasmid-DNA erreicht, während intakte Oozysten nicht transfiziert werden konnten. In HCT-8-
Monolayern lag der IC50-Wert von NTZ bei 60,54 ng/ml (197 nM), während er mit NTZ-R8 deutlich 
auf 4,499 ng/ml (2,9 nM) verringert werden konnte und die In-vitro-Wirksamkeit von NTZ durch 
Koppelung an Octaarginin um das 68-fache signifikant (P < 0,05) gesteigert wurde. In den In-vivo-
Studien zeigten infizierte Mäuse Anorexie, Gewichtsverlust und struppiges Fell. Mit 10 mg NTZ/kg 
KGW behandelte Mäuse hatten eine Überlebensrate von 40 %, während mit 2 mg NTZ-R8/kg KGW 
behandelte Mäuse eine deutlich höhere Überlebensrate von bis zu 80 % aufwiesen, dieser Effekt war 
allerdings nicht signifikant (P > 0.05). 
Schlussfolgerung: Eine neue Methode zur einfachen und schnellen Transfektion von C. parvum, die 
nur eine kleine Menge Plasmid-DNA erfordert und nicht von einer hochmodernen Ausstattung abhängt, 
wurde entwickelt. Die besten Ergebnisse wurden bei der Verwendung von STE-Oozysten erzielt, 
während intakte Oozystenwände nicht permeabel sind. Octaarginin transportierte NTZ in extrazellulär 
und intrazelluläre Stadien von C. parvum und erwies sich in vitro wie in vivo als ein geeignetes Vehikel 
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